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ABSTRACT OF THESIS

IDENTIFYING BISPHOSPHONATE PROTEIN BIOMARKERS IN EQUINE SERA
USING MASS SPECTROMETRY METHODS
Bone resorptive diseases affect humans and horses, alike. Examples of these diseases
include osteoporosis, Paget’s disease, and osteogenesis imperfecta in humans, and
navicular disease in the horse (Mitchell et al., 2019; Suva et al., 2021). Bisphosphonates
are used to treat these diseases, and may remain in the bone for several years after
administration, demonstrating the need for newer drug testing methods.
The purpose of the discovery phase of this study was to use blood samples of intraining horses which had been given an initial administration of the bisphosphonate
tiludronate and identify protein biomarkers that changed in response to this class of drugs.
In the targeted phase, the objective was to validate the previously identified protein
biomarkers that can be added into a biomarker library. This library is meant to be
referenced when drug testing racehorses and can lengthen the detection window of
prohibited or restricted substances.
Fractionation, digestion, and de-salting were performed on sera samples from 19
equine subjects in-training. These samples were injected in an Orbitrap™ Exploris 480d
coupled with an Ultimate 3000 RSLCnanoj. Label-free quantitation of proteins was
performed in both phases. Four key protein biomarkers were identified in the discovery
phase and validated in the targeted phase.
KEYWORDS: Bisphosphonates, Protein Biomarkers, Mass Spectrometry, Bone
Remodeling, Equine
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CHAPTER 1. LITERATURE REVIEW
1.1

Introduction
Bisphosphonates are a class of drugs that are used therapeutically in humans for the

treatment of several diseases, including osteoporosis, Paget’s disease, and bone metastases
(Drake et al., 2008; Suva et al., 2021). There are currently two subgroups of
bisphosphonates: those that contain nitrogen within their side chain and those that do not
(Kamm et al., 2008). Those that contain nitrogen and those that do not have different
mechanisms of action with the common goal of decreasing osteoclast-mediated resorption
of bone during the remodeling process (Drake et al., 2008; Mitchell et al., 2019). In equids,
they are used less frequently, but there are two FDA-approved bisphosphonates for the
treatment of navicular disease: tiludronate and clodronate (Suva et al., 2021). The FDA
approves a final product form of the drug, known as Tildren® or Osphos®, but has not
approved the drug itself before modifications, such as tiludronic acid or clodronic acid.
Tiludronate and clodronate do not contain nitrogen as a part of their side chain. They have
several off-label uses, as well; although, these may prove to be problematic if the off-label
use is in a juvenile horse or an actively training horse (Richbourg et al., 2018).
Bisphosphonates are only approved for use in horses over the age of four because this is
the age when bone remodeling naturally slows (Mitchell et al., 2019). Because these drugs
accumulate in the bone and can remain there for years after administration, caution should
be taken when giving them to juvenile horses due to their potential adverse effects on the
maturation of the epiphyseal plate (Gilday et al., 2020). Furthermore, adult racehorses are
at a higher risk of microcracks and microdamage due to their rigorous training regimens
(Holmes et al., 2014). When bisphosphonates are administered, this can interfere with the
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bone’s natural remodeling ability, thereby perpetuating microcracks and increasing the risk
of fatigue fractures (Gilday et al., 2020).
In the form of anti-doping control, drug testing in equids is of utmost importance in
today’s world because of the production of new designer drugs, as well as drugs that have
rapid elimination times and may not be detected through normal drug tests (Mori et al.,
2015; Wong et al., 2020). These types of substances allow individuals to alter the
performance of a racehorse, while concealing the use of the drug, and ultimately put the
integrity of the breeding and racing industry at risk. There remains a distinction between
prohibited substances and therapeutic substances. Prohibited substances are banned based
on their performance enhancing properties. Therapeutic substances are those which are
prescribed for horse welfare but must be restricted in use to ensure they do not impact
performance on race day. (Wong and Wan, 2014). Bisphosphonates fall into the latter
category, as they are approved for use in the horse for treatment of navicular disease and
are considered controlled substances according to the International Federation for
Equestrian Sports (FEI, 2022). Controlled substances are those which are considered to
have therapeutic use in the horse, but still may affect racing performance, and therefore
must be prohibited (FEI, 2021).
Due to the rather rapid metabolism and excretion of some drugs, protein biomarkers
provide an alternative way to test for the presence of the substance over a longer period.
To assess proteins that may be upregulated or downregulated in response to prohibited
substances, single re-up proteomics using mass spectrometry is a valid technique that
provides this insight (Parker and Borchers, 2014). Mass spectrometry is an excellent way
to perform both discovery-based experiments and targeted analytical methods, alike, in
2

order to identify and validate biomarkers of prohibited substances (Rauniyar and Keck,
2015). There has been a shift from analyzing metabolites to analyzing protein effects in
order to increase the window of time that a prohibited substance can be detected (Barton
et al., 2009).

1.2

Bisphosphonates
Bisphosphonates are a class of drugs aimed at inhibiting osteoclast-mediated bone

resorption. (Mitchell et al., 2019). They were first developed in the 1960s as analogues of
inorganic pyrophosphate—a chemical aimed at inhibiting calcification of blood vessels
(Kamm et al., 2008). Bisphosphonates’ high specificity for hydroxyapatite crystals and
preference for binding to bone is part of what makes them effective inhibitors of bone
resorption (Soto and Chiappe Barbará, 2014). Bisphosphonates are classified into two
groups based on the contents of their side chain: nitrogen-containing and non-nitrogen
containing. The nitrogen-containing bisphosphonates have higher potencies and overall
increased functionalities (Kamm et al., 2008). In humans, these drugs are used in the
treatment of a variety of diseases, including osteoporosis, Paget’s disease, and metastatic
bone tumor pain (Drake et al., 2008). While there are several bisphosphonates that are
widely used in humans, only two drugs in the non-nitrogen containing class are approved
for use in horses: tiludronate and clodronate.
1.2.1

Nitrogen-Containing Bisphosphonates

Nitrogen-containing bisphosphonates are more potent inhibitors of bone resorption
than non-nitrogen containing bisphosphonates because of their greater binding affinity to
bone and hydroxyapatite crystals (Bigi and Boanini, 2018). Drugs in this class include
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risedronate, zoledronate, alendronate, pamidronate, and ibandronate (Soto and Chiappe
Barbará, 2014). These are known as second and third generation bisphosphonates and are
aimed at inducing osteoclast apoptosis (Drake et al., 2008). To do this, the nitrogencontaining bisphosphonates target the mevalonate pathway—a pathway that results in the
production of cholesterol and other sterols (Russell, 2007). The drug inhibits the action of
farnesyl diphosphate synthase, which downregulates the production of farnesyl
pyrophosphate and geranylgeranyl pyrophosphate (Reszka and Rodan, 2003). These two
proteins are responsible for isoprenylation of GTPases that occurs post-translationally
(Drake et al., 2008). The GTPases include those within the Rab, Ras, and Rho families and
are essential for osteoclast activity (Coxon et al., 2006). Osteoclast apoptosis is induced
after the cell becomes unable to perform certain processes, such as formation of the ruffled
border (Mitchell et al., 2019). Other processes that are essential for osteoclast function and
become downregulated due to the inhibition of small GTPases are cytoskeletal arrangement
and vesicular trafficking (Kimmel, 2007).
While the mechanism of action of the nitrogen-containing bisphosphonates is the
same overall, the individual drugs’ relative efficacies differ depending on the nature of
their R-group, whether it contains nitrogen or does not contain nitrogen. There are both
alkyl and heterocyclic R-groups represented in the individual drugs; this can cause at least
a 500-fold difference in the efficacy in which they inhibit farnesyl diphosphate synthase
(Kimmel, 2007).
1.2.2

Non-Nitrogen Containing Bisphosphonates

Non-nitrogen containing bisphosphonates are referred to as first generation
bisphosphonates (Drake et al., 2008). Drugs in this class include clodronate, tiludronate,
4

and etidronate (Soto and Chiappe Barbará, 2014). These substances are also aimed at
inducing osteoclast apoptosis, albeit through a different mechanism (Coxon et al., 2006).
The drugs within this generation are first taken up by the osteoclast and become
incorporated into molecules of ATP through an aminoacyl-transfer RNA synthetase
enzyme, resulting in the production of cytotoxic ATP (Soto and Chiappe Barbará, 2014).
This cytotoxic ATP is non-hydrolyzable and accumulates inside the osteoclast, inhibiting
pathways that are ATP-dependent (Mitchell et al., 2019). It has been observed that the
cytotoxic ATP generated by clodronate inhibits mitochondrial ADP or ATP translocase
and this mechanism leads to apoptosis of the osteoclast (Reszka and Rodan, 2003). There
is a series of events resulting from the mitochondria losing its function that lead up to
introduction of apoptosis. Tiludronate and etidronate have shown similar mechanisms,
although the cytotoxic ATP generated is a lesser amount than that which clodronate
produces (Reszka and Rodan, 2003). They are integrated into molecules of ATP due to the
similarity of their structure with inorganic pyrophosphate (Drake et al., 2008).
1.2.3

Pharmacology

Pharmacology of bisphosphonates has been well studied, including both the
pharmacokinetics (PK) and pharmacodynamics (PD) of the drugs (Cremers and
Papapoulos, 2011). Bisphosphonates are artificial compounds that originate from inorganic
pyrophosphate with the geminal oxygen being replaced by a carbon to create a
phencyclidine bond. These drugs are more stable than endogenous pyrophosphate because
the phencyclidine bond is resistant to heat and enzymatic hydrolysis (Reszka and Rodan,
2003). One of the most important aspects of bisphosphonates’ pharmacology is their
bioavailability depending on the route of transmission (Drake et al., 2008). However,
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according to Soto, their main pharmacological effect is their ability to strengthen bone
through various mechanisms (Soto and Chiappe Barbará, 2014).
Pharmacokinetics and pharmacodynamics encompass several different aspects of
bisphosphonates. Pharmacokinetics assesses how the drug moves throughout the body and
includes absorption, distribution, and skeletal elimination (Lin, 1996). Pharmacodynamics
discusses the effects of the drug on the body and include the drug’s mechanisms of action
(Cremers and Papapoulos, 2011).
1.2.3.1 Pharmacokinetics of Bisphosphonates
Bisphosphonates, when ingested orally, have low bioavailability (Lin, 1996). They
are taken up in different portions of the gastrointestinal tract and into the blood stream
through varying mechanisms of transport, including active and paracellular transport
(Cremers et al., 2019). Absorption of bisphosphonates in the gastrointestinal tract has been
shown to change as stomach pH increases/decreases (Cremers and Papapoulos, 2011).
Studies have shown the oral bioavailability in rats can decrease as much as 6- to 7-fold
when given with food (Porras et al.). Their low oral bioavailability is thought to be due to
their low lipophilicity. This characteristic prevents transcellular transport—a type of
transport where the drug is taken up into the bloodstream through epithelial cells (Lin,
1996). Drugs in the bisphosphonate class tend to be characterized pharmacokinetically due
to their similar absorption rates. Due to their poor oral bioavailability in humans,
bisphosphonates are administered intravenously or intramuscularly in horses (Soares et al.,
2016).
Once in the bloodstream, bisphosphonates tend to bind to plasma and serum proteins.
Binding varies depending on the bisphosphonate but has been shown as lower in the plasma
6

due to endogenous displacers (Cremers et al., 2019). The drug does not typically undergo
first or second phase metabolism, with the exception of the incorporation of non-nitrogen
containing bisphosphonates into ATP to create cytotoxic ATP analogues (Cremers et al.,
2019). Bisphosphonates can be found in the liver, spleen, and other soft tissues after
distribution occurs (Cremers and Papapoulos, 2011). Because bisphosphonates cannot
easily penetrate cell membranes, their exposure to non-target tissues is decreased (Reszka
and Rodan, 2003). The amount of drug which is not found in these tissues will either be
excreted through the kidneys or taken up into the bone (Cremers and Papapoulos, 2011).
If the bisphosphonate is taken up into the bone, they tend to congregate in areas of high
bone turnover, causing their distribution in bone to be highly heterogeneous (Soares et al.,
2016). Due to this heterogenous distribution pattern, bisphosphonates tend to be
endocytosed into osteoclasts. Once inside the osteoclast, the individual bisphosphonates
follow their mechanisms of action in order to decrease bone resorption rates, whether that
is by accumulation of cytotoxic ATP analogues or disruption of the mevalonate pathway
(Soares et al., 2016).
Bisphosphonates have a relatively slow elimination from the skeleton, which may be
due to the drug becoming embedded in the bone and only being released after future
resorption (Cremers and Papapoulos, 2011). They exhibit a multiple phase elimination
process (Porras et al.). The amount of drug that becomes immersed in bone after
ossification is likely inactive until it is released again following resorption (Cremers et al.,
2019). As a consequence of their slow elimination time, several studies have shown
bisphosphonates in the urine many years after administration (Riggs et al., 2001; Soares et
al., 2016).
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Excretion may occur either through bile or urine, depending on the drug and its
properties. For bisphosphonates, the primary route of excretion is renally, with bile
excretion being relatively insignificant (Lin, 1996). Alendronate, when given orally, was
detected at a very low percentage in the feces (<0.2%), which suggests that excretion
through the bile is minimal (Porras et al.). Alendronate has a terminal half-life in humans
estimated at ten years. Pamidronate has been detected in urine up to eight years postadministration. Both findings suggest a slow elimination of bisphosphonates from the
skeleton (Baroncelli and Bertelloni, 2014).

1.2.3.2 Pharmacodynamics of Bisphosphonates
The main pharmacodynamic effect of bisphosphonates on the body is their ability to
significantly reduce bone resorption (Soto and Chiappe Barbará, 2014). During treatment
of Paget’s disease in humans, collected data showed an initial decrease in bone resorption
which led to a slowed decrease in bone formation because these two processes are coupled
within bone remodeling (Cremers and Papapoulos, 2011). Biochemically, the nitrogencontaining bisphosphonates work by disrupting the mevalonate pathway and preventing
prenylation of signaling proteins, leading to loss of osteoclast functionality (Cremers et al.,
2019). On the other hand, the non-nitrogen containing bisphosphonates act by creating
cytotoxic ATP after they are metabolized in the osteoclast, thereby inhibiting ATPdependent intracellular pathways necessary for osteoclast function and survival (Soto and
Chiappe Barbará, 2014).
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Not only do bisphosphonates work to inhibit osteoclast activity, but they have also
been shown to increase viability of bone-forming cells, such as osteoblasts and osteocytes
(Cremers et al., 2019). Because the mode of action of bisphosphonates on osteoblasts and
osteocytes happens at concentrations lower than that of their effects on osteoclasts, it is
likely that they are acting on these cells through different mechanisms (Soto and Chiappe
Barbará, 2014).
1.2.4

Reason for Use in Veterinary Medicine

Bisphosphonates were originally developed for use in human medicine to treat
diseases such as osteoporosis, Paget’s disease, multiple myeloma, bone metastases, and
several childhood skeletal disorders including osteogenesis imperfecta (Cremers et al.,
2019). Studies involving bisphosphonate use in veterinary medicine are limited but have
grown in the last 10-20 years (Suva et al., 2021).
These drugs are not only used in equids, but have implications in small animal
medicine, as well. Bisphosphonates are popularly used in veterinary oncology for palliative
care of bone tumors in dogs (Suva et al., 2021). These tumors often cause excruciating pain
leading to a decreased quality of life, warranting amputation of the affected limb (Tomlin
et al., 2000). However, amputation may not always be possible due to other factors, which
is why bisphosphonates have been incorporated as an analgesic mechanism. Dogs being
treated for bone tumor pain are frequently prescribed the nitrogen-containing
bisphosphonates, pamidronate and zoledronate, which are the two most common
bisphosphonates administered for this disease (Suva et al., 2021).
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Feline hypercalcemia may also be treated with bisphosphonates such as pamidronate
and alendronate (Suva et al., 2021).
Within equine veterinary medicine, tiludronate and clodronate are the only FDAapproved bisphosphonates. They are intended for the treatment of navicular disease and
controlling symptoms associated with disease onset in horses aged four or older (Mitchell
et al., 2019). Navicular disease is an inflammatory condition that affects any of the
components of the trochlear apparatus of the foot, including the navicular bone (Soto and
Chiappe Barbará, 2014). Symptoms that arise with navicular disease include pain and
lameness. Several studies have shown that clodronate (Osphos) is effective at reducing
lameness in horses who have navicular disease (Markell et al., 2020). However, both
tiludronate and clodronate are effective at controlling lameness symptoms of navicular
disease (Richbourg et al., 2018). Any administration of bisphosphonates that is not
specifically for navicular disease is considered off-label use and has not been FDAapproved due to lack of available studies (Mitchell et al., 2019).
Bisphosphonates have also been effective in off-label use for treatment of distal tarsal
osteoarthritis (bone spavin) and chronic back pain (Suva et al., 2021). Currently, two
studies have assessed the efficacy of tiludronate in the treatment of bone spavin. Both
studies assessed lameness clinical score and showed optimal improvement in lameness two
months after administration (Gough et al., 2010; Soto and Chiappe Barbará, 2014). In the
second study, compared to placebo, horses treated with tiludronate for lameness caused by
bone spavin had a significant improvement in their lameness score at 60 days. If horses
were treated again on day 60 with tiludronate, they showed further improvement at 120
days compared to placebo horses (Gough et al., 2010)
10

1.3

Mass Spectrometry
Mass spectrometry represents several different mass analyzing, detection, and

ionization methods (Zubarev and Makarov, 2013). The goal of mass spectrometry is to
measure the mass-to-charge ratios of ions in the gas phase (Lane, 2005). It is widely used
in molecular research, including proteomics experiments (Savaryn et al., 2016). While
proteomics may be connotative to a discovery-based experiment, certain mass
spectrometers, such as a triple quadrupole or Orbitrapsd, can perform targeted experiments
using single reaction monitoring (SRM), multiple reaction monitoring (MRM), or parallel
reaction monitoring (PRM) methods (Addona et al., 2009; Doerr, 2012; Rauniyar and
Keck, 2015). Utilizing either bottom-up or top-down techniques, the mass spectrometer is
able to control and use the fragmentation data that is generated efficiently for identification
of specific mass-to-charge ratio (m/z) ions (Mann and Kelleher, 2008).
1.3.1

Discovery Methods

Proteomics is the study of the proteome, which is the complete set of proteins
expressed by the genome (Amiri-Dashatan et al., 2018; Dupree et al., 2020). This branch
of science aims to identify, characterize, and quantify the proteins which constitute a
proteome (Lane, 2005).
In proteomics, biomarkers can be identified beginning with a discovery phase, which
is performed using non-targeted techniques. One goal of protein biomarker selection is to
determine whether specific proteins have been upregulated or downregulated (Parker and
Borchers, 2014). These proteins are found to be contrastingly expressed between a normal
and diseased state(s) (Rifai et al., 2006). Proteins detected in the discovery phase are known
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as candidate proteins and/or candidate biomarkers and must be verified through a targeted
method (Ronsein et al., 2015).
The discovery phase typically utilizes shotgun proteomics, also known as bottom-up
proteomics (Parker and Borchers, 2014). In bottom-up proteomics, the protein is digested
with an enzyme such as trypsin, and the peptides are then analyzed in the mass spectrometer
using either electrospray ionization (ESI) or matrix-assisted laser desorption ionization
(MALDI) techniques (Chait, 2006). However, when using trypsin, due to its high
efficiency, up to 56% of the peptides that are produced may be too small to be detected by
mass spectrometry. Most data analysis tools and software are optimized for tryptic
properties, so bottom-up techniques may lead to a restricted view of the proteome (Dupree
et al., 2020). Even still, bottom-up proteomics has been used by scientists for several years
for quantifying proteins, protein modifications, and profiling the proteome (Zhang et al.,
2013). Proteins are monitored by peptides because of their efficient ionization and
predictable fragmentation patterns (Dupree et al., 2020).
Serum in both humans and equids is a complex matrix due to the high abundance of
endogenous proteins, like albumin, which are proteins that can negatively affect mass
spectrometric assays (Liu et al., 2014). During the discovery phase, there are many
challenges that must be faced. One challenge is that serum proteins in this phase tend to
make samples highly complex and variable. This can be dealt with by depleting proteins
which are of high abundance or through fractionation of a sub-proteome (Gillet et al.,
2016). Depending on the nature of the sample, it may be essential to perform a depletion
to reduce the complexity. This is especially true of serum, which is made up of 50%
albumin (Dupree et al., 2020).
12

1.3.2

Targeted Methods

Once the discovery method has identified candidate biomarkers, these proteins need
to be qualified, verified, and validated using a targeted method (Parker and Borchers,
2014). The qualification step ensures that the differential expression of candidate
biomarkers seen in the discovery step can also be seen using a targeted method (Rifai et
al., 2006). Verification is used to confirm that the expression of candidate biomarkers can
be seen in a greater number of samples than what was used in the discovery method (Rifai
et al., 2006). Validation of biomarkers requires an even larger number of samples—many
more than the qualification and verification (Zhang et al., 2013).
Many different methods can be utilized to perform targeted acquisitions. These
methodologies include single reaction monitoring (SRM); multiple reaction monitoring
(MRM), which is also known as selected reaction monitoring, or SRM; and parallel
reaction monitoring (PRM). The triple quadrupole mass spectrometer is the optimal
instrument for MRM experiments (Gillet et al., 2016; Liebler and Zimmerman, 2013).
In MRM, a target peptide’s mass is identified and selected in the first quadrupole
(Q1), fragmented in the second quadrupole (Q2), and generated fragments are then
measured in the third quadrupole (Q3) (Picotti and Aebersold, 2012). The goal of an MRM
experiment is to analyze a specific product ion derived from a precursor ion, termed Q3
and Q1, respectively. This allows for high sensitivity in the presence of a busy background
(Sherman et al., 2009). By utilizing a triple quadrupole instrument, MRM is able to analyze
complex mixtures of proteins and identify peptides which may be less abundant (Savaryn
et al., 2016). In order to monitor analyte ions and their corresponding product ions, MRM
utilizes the triple quadrupole instrument’s ability to help develop assays, otherwise known
13

as MRM transitions, which must be optimized to verify optimal performance (Doerr,
2012). Three types of information must first be identified to complete an MRM analysis:
(1) proteins that make up the target protein set, (2) peptides with good mass spectrometric
responses and which discern the identified target proteins, and (3) the fragments which
discriminate the peptides from other components in the sample (Lange et al., 2008). One
of the challenges accompanying MRM proteomic analyses is the background and the
analytes are both composed of peptides, which can sometimes lead to a limit of detection
(LOD) (Gallien et al., 2013). However, MRM methods, when performed on a triple
quadrupole mass spectrometer, have become the “gold standard” for targeted proteomics
(Peterson et al., 2012). This is due to the predetermined scanning events and m/z ions
associated with a target peptide that allow the triple quadrupole mass spectrometer to
readily identify targeted ions in complex matrices.
On the other hand, PRM can be performed on quadrupole-Orbitrap mass
spectrometers, where the Orbitrap instrument takes the place of Q3 (Rauniyar and Keck,
2015). Orbitrap mass spectrometers have the benefit of allowing one to perform both
discovery and targeted methods on the same instrument (Dupree et al., 2020). PRM has
been shown to generate high resolution data and act as a powerful method of targeted
analysis (Liebler and Zimmerman, 2013). In contrast to MRM methods where selected
transitions are monitored within an experiment, PRM methods allow use of a single
analysis to monitor all fragmented ions, subtracting the need for tedious optimizations
(Doerr, 2012). PRM is highly specific because all potential product ions, rather than just
three to five selected transitions, are analyzed and used to validate peptide identity
(Peterson et al., 2012). This makes PRM more selective than MRM due to better
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differentiation of the targeted peptide from any background or interferences that may elute
at the same time (Shi et al., 2016).
In a study comparing MRM’s and PRM’s ability to quantify proteins in a lipid
nanoparticle, the results showed that they were comparable in their precision and
repeatability as well as their linearity and dynamic range (Ronsein et al., 2015). PRM
provides an efficient alternative route in the absence of MRM (Gallien et al., 2013).

1.4

Equine Bone Remodeling
Bone remodeling in humans is the process by which bone cells couple resorption and

ossification in order to repair bone tissue (Suva et al., 2005). This same process occurs in
horses. Bisphosphonates, such as tiludronate and clodronate, are aimed at inhibiting the
resorption process that is central to bone remodeling in equids (Richbourg et al., 2018).
Bone remodeling also has implications in current controversies in the horse racing world.
Off-label use of bisphosphonates may occur in an attempt to improve the radiographs of
young Thoroughbreds who are affected by sesamoiditis and are entered into a sale. This
use is assumed to decrease bone resorption and potentially increase bone ossification,
resulting in improved visuality on the radiograph; however, there is no direct evidence of
this phenomenon (Suva et al., 2021). It has also been suggested, in racehorses, that
bisphosphonates may be useful to prevent or treat several different diseases, including
osteoarthritis and stress fracture risk (McLellan, 2017).
1.4.1

Racehorses

Thoroughbred racehorses are continually going through bone remodeling processes
due to their rigorous training (McLellan, 2017). They often suffer from bone fatigue when
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undergoing intense exercise, something that can increase the amount of microdamage and
microcracks (Holmes et al., 2014). Microcracks can spread further if bisphosphonates have
been administered and remodeling has not initiated due to the inhibition of osteoclastic
resorption (McLellan, 2017). Fatigue injuries occur in “high load environments” and result
from the fast accumulation of microcracks that cannot be repaired quickly due to the
reduction in osteoclasts (Holmes et al., 2014; Smith et al., 2016). Fatigue fractures that
occur in young Thoroughbred racehorses are located in the third metacarpal bone 70% of
the time and are seen within the first year of training (Nunamaker et al., 1990). Many horses
are able to work through these fractures with a brief respite from training (R Carpenter
2022, personal communication, 13 April). There have been studies that show more
fractures occur during training than in racing, and this is likely due to the fact that horses
train each week but only race every three to four weeks (Bailey et al., 1999).
In studies assessing the differences in bone remodeling in horses that are training
versus those that are resting, it has been observed that actively training horses have lower
levels of bone resorption and higher levels of bone formation due to an increase in habitual
loading on certain bones (Holmes et al., 2014). In the racehorse, various diseases may occur
due to inappropriate bone remodeling activity, which results from failing to adapt to high
rates of strain placed on the affected bone (McLellan, 2017). These diseases include
palmar/plantar osteochondral disease, sclerosis of the third carpal bone, and stress fractures
of the tibia and pelvis (McLellan, 2017).
During fracture repair in mice, osteoclasts are a vital component to the efficiency of
the restoration (Lin and O’Connor, 2017). Clodronate, when used during fracture healing,
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has the potential to reduce normal bone healing in equids due to its inhibition of osteoclast
recruitment (Richbourg et al., 2018).
Because bisphosphonates have the potential to interfere with normal bone
development in juvenile racehorses and may increase fatigue fracture risk in adult
racehorses, these drugs should be administered with caution when treating various
orthopedic conditions in order to protect the welfare of the horse (Gilday et al., 2020;
McLellan, 2017).
1.4.2

Radiograph Clearings of Young Horses

Thoroughbred yearlings are subjected to an examination before they are purchased at
auctions. These examinations place a lot of importance on radiographic evidence of
anything that may impair future racing (Spike-Pierce and Bramlage, 2003). At the time of
these yearling auctions, sesamoiditis has been reported as the most common diagnosis from
a radiograph (Mclellan and Plevin, 2013).
Equine sesamoid bones are susceptible to poor healing due to the lack of blood
supply, as well as lack of musculature around them (Suva et al., 2021). Because of their
location, sesamoid bones are vulnerable to increased force, tension, and fracture risk. These
risks are intensified in young racehorses (Suva et al., 2021). It has been seen that some
veterinarians may utilize bisphosphonates in the treatment of sesamoiditis of young (e.g.,
yearling) Thoroughbreds due to the assumption that these drugs heal the disease, at least
visually on a radiograph (McLellan, 2017). This use of bisphosphonates is not supported
by research. Bisphosphonates, when administered to young racehorses in this manner, may
interfere with normal bone development, such as maturation of the epiphyseal plate (Gilday
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et al., 2020). Because these drugs can have harmful effects on bone processes in horses
under the age of four, caution should be taken when administering them to juvenile
racehorses.

1.5

Biomarker Detection
Drug testing in performance horses, particularly those that compete in races, is of

utmost importance to verify that races are won based on a horse’s athletic ability, to avoid
putting at risk the ethics of the horse breeding industry, and to ensure the welfare of horses
and their riders (Fragkaki et al., 2017). There must be a strict balance between allowing
therapeutic drugs for the welfare of the horse, while also protecting the integrity of the
industry by ensuring those drugs are no longer affecting the horse when it comes time to
race (Wong and Wan, 2014).
Drugs are metabolized quickly in the horse. The purpose of analyzing biomarkers is
to be able to detect drug use across a longer sampling time period. The use of biomarkers
allows for the possible detection of prohibited substances by discovery of compounds that
persist in the biological system well after the original drug has been excreted (Cawley and
Keledjian, 2017). Assessing the effects that drugs have on various proteins within the horse
provides a wider time frame for drug detection and allows for observations of changes that
may not be detectable through metabolites (Cawley and Keledjian, 2017). Equine doping
has recently changed from small molecules to substances like designer drugs—a change
that requires a shift of focus to analyzing the effects of doping, or what biological changes
are generated through these agents (Barton et al., 2009).
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1.5.1

Equine Drug Metabolism and Protein Biomarkers

Biomarkers are defined as “any measurable parameter altered as a result of a
challenge to an individual’s system” (Cawley and Keledjian, 2017). Drug metabolism in
equids is not a well-studied area. Compared to human metabolism data, there is not as much
drug metabolism data for horses because the veterinary pharmaceutical industry does not
require as much information regarding metabolism for the approval of drugs (Scarth et al.,
2011). Drug metabolism studies in equids often require the use of in vivo experiments,
which can be difficult to obtain approval for due to the ethical aspects of animal
experimentation (Scarth et al., 2010). In order to utilize metabolites in the detection of
prohibited substances, the drug’s metabolism must be understood, which can prove to be
ethically problematic with recently developed drugs, such as designer steroids, due to lack
of toxicology data (Fragkaki et al., 2017).
1.5.2

The Shift from Equine Metabolite Biomarkers to Equine Protein Biomarkers

Metabolites are often used in identification and/or detection of drugs which are highly
metabolized and may only be detected by discovery of their metabolites (Waller and
McLeod, 2017). These can be useful even if no initial substance is detected (Waraksa et
al., 2019). However, when metabolism studies are performed in vivo, metabolites in urine
are often quite complicated to detect due to various reasons. These reasons include
interferences that complicate identification, long experimental timescales, and the
difficulty of determining certain enzymes that play a role in the metabolism of the drug
(Scarth et al., 2010). In response to this, drug metabolism studies can be carried out in vitro,
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which can be more advantageous than in vivo studies, although there are still limitations
that come with these types of analyses (Scarth et al., 2010).
In recent years, new drugs have been developed that are not as detectable as drugs
that have been used in the past. This is where biomarkers become useful because they can
be utilized to identify the effect that a drug has on a biological system without requiring
detection of the drug itself (Wong et al., 2020). There are also certain drugs, like anabolic
steroids, that have rapid elimination times, making them difficult to detect in normal doping
tests. This leads to the need for different ways to identify these types of substances, such
as looking for upregulation of various proteins that is an indirect result of the drug (Mori
et al., 2015).
For these types of doping tests, equine plasma is a fitting medium as it is routinely
sampled and it tends to be abundant in biomarkers (Barton et al., 2009). Compared to urine,
plasma acts as a better indicator of the effect of the drug, with few exceptions (Toutain,
2010). However, plasma also contains proteins such as albumin that can complicate
purification of target biomarkers (Bailly-Chouriberry et al., 2008).
Overall, using metabolites to detect drug use in horses is decreasing in favor of
protein biomarkers that are changed in response to the prohibited substance, thereby
increasing detection windows (Ho et al., 2015).

1.6

Summary
Bisphosphonates are becoming more relevant for use in the racehorse due to

assumptions that this class of drugs may increase bone strength, decrease pain associated
with disease, or visually clear radiographic evidence of sesamoiditis when Thoroughbreds
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go up for auction as yearlings. Because bisphosphonates have a rapid elimination time, it
is difficult to analyze any metabolites.
With the introduction of new drugs that are being designed to conceal substance use
in racehorses, there is a need for a better detection method that goes farther than analyzing
metabolites. Bottom-up proteomics techniques performed on Orbitrap instruments allow
for the shift to occur to analyzing drug effects on proteins within the biological system
while increasing the window in which the drug can be detected.
Biomarkers are an important aspect of drug testing in performance horses. These
permit the detection of prohibited substances by analyzing proteins that may be upregulated
or downregulated in comparison with the same proteins in a normal, untreated horse.
In order to protect the welfare of racing Thoroughbreds, as well as the integrity of the
breeding and racing industry, there must be better drug testing implemented that can assess
the use of performance drugs and therapeutics, such as bisphosphonates. This can be
accomplished by utilizing biomarker detection and proteomics methods, both of which can
increase the window of time in which a prohibited substance can be detected.
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CHAPTER 2. IDENTIFICATION OF BISPHOSPHONATE PROTEIN BIOMARKERS USING A
MASS SPECTROMETRY DISCOVERY METHOD
2.1

Introduction
Equine drug testing has become more important over the last several years due to

various factors, such as the development of designer drugs—drugs that are rapidly
eliminated from the biological system and make it nearly impossible to detect through
normal drug testing techniques. These types of substances put at risk the integrity of the
breeding industry, as well as the welfare of the horses that are administered these drugs
(Fragkaki et al., 2017). Because of this, there must be new techniques developed for drug
testing to increase the window of time in which prohibited substances can be detected in
the performance horse. Protein biomarkers, which have changed in response to the
administration of some substance, such as a bisphosphonate, allow for increased detection
windows of banned substances.
Bisphosphonates are a therapeutic class of drugs that are used to inhibit bone
resorption in humans, small animals, and equids for various reasons (Suva et al., 2021).
Nitrogen-containing bisphosphonates can be up to 10,000 times more potent than nonnitrogen containing bisphosphonates (Kamm et al., 2008). In humans, they are used to treat
bone resorptive diseases such as osteoporosis; Paget’s disease of bone; metastatic bone
tumor pain; and childhood skeletal disorders, such as osteogenesis imperfecta (Soares et
al., 2016). In small animals, they can treat feline hypercalcemia, as well as bone tumor pain
in dogs (Suva et al., 2021; Tomlin et al., 2000). Currently, there are two FDA-approved
non-nitrogen containing bisphosphonates for the treatment of navicular disease in horses:
tiludronate and clodronate.
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Bisphosphonates inhibit bone resorption by targeting the bone resorptive cells,
osteoclasts, for apoptosis. Non-nitrogen containing bisphosphonates create cytotoxic
analogues of ATP, which in turn inhibits ATP-dependent pathways that the osteoclast relies
on for survival (Mitchell et al., 2019; Soto and Chiappe Barbará, 2014). Osteoclasts depend
heavily on ATP generation, which is why they are full of mitochondria. The non-nitrogen
containing bisphosphonates are thought to inhibit the ADP/ATP mitochondrial translocase
inside the osteoclast, leading to a series of events that cause apoptosis (Reszka and Rodan,
2003). Nitrogen-containing bisphosphonates target the mevalonate pathway, which is
responsible for the production of cholesterol and other sterols (Russell, 2007). This
pathway also results in the isoprenylation of proteins, such as small GTPases that are
necessary for osteoclast function and survival (Coxon et al., 2006). By inhibiting the
enzyme farnesyl diphosphate synthase, nitrogen-containing bisphosphonates inhibit this
isoprenylation and further block the formation of the osteoclastic ruffled border, vesicular
trafficking, and cytoskeletal arrangement resulting in apoptosis of the osteoclast (Kimmel,
2007; Mitchell et al., 2019).
Bisphosphonates have low oral bioavailability, which is why they are frequently
administered in the horse either intravenously or intramuscularly (Cremers et al., 2019;
Soares et al., 2016). Uniquely, bisphosphonates do not undergo phase one or two
metabolism. These drugs are taken up into bone or excreted renally (Cremers and
Papapoulos, 2011). If taken up into bone, they tend to congregate in areas of high bone
turnover, making their distribution highly heterogeneous. Their skeletal elimination is very
slow, and studies have found evidence of bisphosphonates in the urine years after
administration (Riggs et al., 2001; Soares et al., 2016).
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Equine athletes experience continuous bone remodeling due to their rigorous training
modules (McLellan, 2017). This training can also cause racehorses to undergo bone
fatigue, a phenomenon that increases the risk of microcracks and microdamage (Holmes et
al., 2014). When bisphosphonates are administered and bone remodeling is impaired due
to the lack of osteoclast-mediated resorption, microcracks may spread further because they
are unable to be repaired by normal remodeling processes (McLellan, 2017). The
perpetuation of the microcracks can increase the risk of fatigue injury in the horse’s high
loading environments (Holmes et al., 2014; Smith et al., 2016). For this reason,
bisphosphonates should be administered with caution in adult Thoroughbred racehorses.
In some instances, juvenile racehorses may be administered bisphosphonates to treat
sesamoiditis. This occurs because of the assumption that bisphosphonates visually clear
signs of the disease on a radiograph and may make these horses more attractive as yearlings
when they go to auction (McLellan, 2017; Suva et al., 2021). This use of bisphosphonates
is not supported by research. Bisphosphonates are only approved for use in horses over the
age of four because this is when bone remodeling naturally slows (Mitchell et al., 2019).
Administration of this class of drug in horses under the age of four may interfere with
normal remodeling processes and have harmful effects on the bone development of the
juvenile horse. Caution should be taken when giving bisphosphonates to young horses for
this reason.
Bisphosphonates are drugs that are rapidly excreted from the urine and make it
difficult to use normal drug testing techniques to confirm their administration. This is true
for many of the new designer drugs that are hard to detect metabolically, which can increase
their risk for abuse in equine athletes (Barton et al., 2009). To lengthen the window of time
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in which these drugs can be detected in the horse, a study was conducted in which equine
sera samples were analyzed for proteins that may be upregulated or downregulated in
response to the administration of bisphosphonates.
Utilizing a bottom-up proteomics method for analysis of equine sera samples and
identification of biomarkers requires that the proteins in the samples be digested into their
subsequent peptides. Trypsin, the gold standard of enzymatic digestion of proteins, was
chosen to digest these samples due to its efficiency, inexpensiveness, and resistance to
autolysis (Gillet et al., 2016; Switzar et al., 2013). In bottom-up proteomics, digestion is
an essential step to ensure high quality identification of proteins (Switzar et al., 2013).
Trypsin may not always be the optimal choice for enzymatic digestion due to a number of
factors, so proteases such as pepsin or endoproteinases like Arg-C and Asp-N may be used
instead (Switzar et al., 2013). In addition to enzymatic digestion techniques, nonenzymatic
cleavage may also be used in bottom-up proteomics to break down the protein.
Electrochemical oxidation is a method which occurs at the amino acids tyrosine,
tryptophan, histidine, cysteine, and methionine resulting in specific cleavage of the peptide
bond that is C-terminal to tyrosine (Permentier and Bruins, 2004).
After digestion of proteins, the peptides must be de-salted and freed of contaminants
before injection into the Orbitrap™ mass spectrometerd. Any excess salts or detergents can
interfere with the mass spectrometry analysis and may contribute to unwanted background
noise, so a clean-up step is frequently employed (Gundry et al., 2009). Solid phase
extraction (SPE) is a method that is widely utilized in proteomics, which is why Strata-X
SPE C18 columns were used for the purposes of cleaning up equine sera samples in both
phases of this study (Tubaon et al., 2017).
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Mass spectrometry is the optimal method for proteomics, which includes analyzing
complex protein samples (Aebersold and Mann, 2003). To analyze the proteins that have
changed in response to bisphosphonate administration, an Orbitrap™ mass spectrometerd
was used to conduct discovery-based and targeted experiments. A bottom-up proteomics
technique was used, where the protein is digested with trypsin and the resulting peptides
are analyzed in an Orbitrap™ mass spectrometerd (Chait, 2006). The OrbitrapTM Exploris
480d used in this phase was the optimal instrument due to its high resolving power of
480,000 full width at half maximum (FWHM) resolution. Analysis of complex proteomes,
such as the ones being examined in this study, is frequently best completed using high
resolution technologies, which is why samples were analyzed using the OrbitrapTM
Exploris 480d (Mann and Kelleher, 2008). This instrument also employs nanoflow
technology. In order to detect low abundance endogenous proteins, methodologies must be
highly sensitive, a characteristic not available by conventional liquid chromatography.
Nanoflow is a methodology developed to utilize low flow rates that result in higher
analytical sensitivity for detection of peptides, making nanoflow an optimal technique for
the identification of low abundance biomarkers (Cutillas, 2005). Data generated on the
Orbitrap™ mass spectrometerd is analyzed using Proteome Discoverer™ (PD) Version
2.4e. This software has evolved to address several different types of proteomic workflows,
including the label-free quantitation that is used in this study. Advantages of PDe that
factored into its use for the discovery phase include flexible data input from several
different sources, direct access to the MS/MS spectra aiding in identification, and the ease
of exporting data into an inclusion list format that can be used on the Orbitrap™ mass
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spectrometerd for verification of identified biomarkers in the targeted phase (Orsburn,
2021).
Biomarkers can be identified in the discovery phase, but must be validated using a
targeted method, such as PRM. PRM is a way to generate higher resolution data while
subtracting the need for time-consuming optimizations (Doerr, 2012; Liebler and
Zimmerman, 2013). It allows for the simultaneous detection of transitions, which is more
efficient than SRM or MRM.
The goal of this chapter is to analyze the effects of bisphosphonates on different
proteins and identify those which are relevant and can be used in the future as biomarkers
of bisphosphonate administration.

2.2

Materials and Methods
2.2.1

Administration Studies

A total of 19 horses (n = 19) were given a single administration of Tildren®,
manufactured by Bimeda, at 1.0 mg/kg intravenously over a 90-minute period. These
horses were all anonymous, so no information regarding age or sex was given. Serum was
collected over a monitored time course, described in Table 2-1. Horses were in-training
across the time course. The samples were collected at the convenience of the veterinarian,
which is why not all time points are represented.
2.2.2

Sample Preparation

All reagents and chemicals used are Optima® or ReagentPlus® LC/MS grade and are
manufactured by Fisher Chemical or Sigma-Aldrich. Master horse sera samples were
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analyzed in conjunction with the 19 horse samples as a baseline control. The master horse
sera samples were a pool of normal horses. They are different horses than those focused on
in this study and were not sampled on the same days as the 19 equine subjects. These horses
are presumed to be normal and were not administered any substance prior to sampling.
They were prepared for LC-MS/MS injection the same way as the 19 equine subjects in
this study.
2.2.2.1 Organic Solvent Fractionation
In order to effectively analyze proteins in equine sera through LC-MS/MS
techniques, abundant endogenous proteins must be considered and dealt with accordingly.
These proteins can interfere with LC-MS/MS analysis and must be removed to increase
the sensitivity and ruggedness of assays. The most abundant endogenous protein in sera is
albumin, which makes up about 50% of the total protein. There have been several
techniques developed to remove this abundant protein, but the most suitable for this study
was an isopropanol/trichloroacetic acid (IPA/TCA) fractionation (Liu et al., 2014). This
solvent fractionation method is able to remove 95% of the albumin and recover almost
100% of target proteins (Liu et al., 2014). The protocol used for this experiment is based
on the IPA/TCA fractionation optimized by Liu et al. (2014).
A solution of 1% TCA in IPA was prepared in a volume of 5000 µL. Equine serum
(20 µL) was aliquoted into 1.5 mL Eppendorf tubes. Into the tubes, 200 µL of IPA/TCA
solution was added, followed by two minutes of vortexingl to mix. The tubes were placed
in the centrifugei at 5⁰C and spun at 1500 x g for five minutes. The albumin-containing
supernatant of IPA/TCA was removed and saved for later analysis. The pellet was washed
with 200 µL of methanol, followed by 30 seconds of vortexingl to mix. The tubes were
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placed back into the centrifugei at 5⁰C and spun at 1500 x g for 2 minutes. The supernatant
containing methanol was removed and saved for later analysis. The pellet, containing
precipitated serum proteins, was placed in a -20⁰C freezer until digestion.
2.2.2.2 Tryptic Digestion
For the purposes of analyzing proteins that may have been changed in response to
bisphosphonate administration, a bottom-up proteomics technique was used. This method
involves breaking down the protein into individual peptides, analysis of peptides using LCMS/MS technology, and piecing together the resulting information to reveal the protein
characteristics (Gundry et al., 2009). To break down the protein into peptides, enzymatic
digestion is a popular route to follow. For the purposes of this study, the enzyme used was
trypsin. Trypsin is a favored enzyme because of its inexpensiveness, robustness, as well as
its ability to generate certain size peptides that are optimal for chromatographic analysis
(Gillet et al., 2016).
Several solutions were prepared for this step, including 75 mM ammonium
bicarbonate (ABC), 200 mM dithiothreitol (DTT), iodoacetamide (IAA), and 1 µg/µL
trypsin. Double-distilled waterb was added to both ABC and DTT after appropriate
amounts were weighed. IAA was weighed out and the appropriate amount of ABC to add
was calculated and adjusted if needed due to the light sensitivity of IAA. ABC was not
added to the IAA until it was needed for digestion. Stock trypsin was diluted to an active
concentration of 1 µg/µL in 75 mM ABC during the last step of digestion.
Previously fractionated protein pellet samples were resuspended in 1000 µL of 75
mM ABC and vortexedl rapidly to ensure adequate resuspension. For each sample, 6.25
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µL was deposited into a 1.5 mL Eppendorf tube for digestion. To these tubes, 50 µL of 75
mM ABC, 7 µL of 100% acetonitrile (ACN), and 3.5 µL of 200 mM DTT were added. The
tubes were vortexedl to mix, and pulse centrifugedh to ensure removal of components from
the side of the tube. The tubes were then placed on a heating block at 37⁰C for one hour.
After this incubation, the 200 mM IAA was brought to its calculated volume with ABC.
Nine µL of prepared 200 mM IAA were added to each tube, followed by vortexingl to mix,
and pulse centrifugationh. The tubes were then placed in a drawer to incubate in the dark
for 30 minutes at room temperature. After this incubation, stock trypsin was diluted with
ABC to its active concentration (100 ng/µL). The samples were diluted with 50 µL of 75
mM ABC. Two µL of active trypsin was added to each tube, followed by vortexingl to mix,
and pulse centrifugationh. The samples were placed on the heating block at 37⁰C for
overnight incubation. After this incubation, the samples were placed in the freezer to stop
the digestion.
2.2.2.3 Strata Column Clean-Up
To optimize the data generated on the LC-MS/MS, the samples needed to have
contaminants removed while retaining target proteins at the best recovery rate. For this,
Strata-X SPE columns were used. The manufacturer’s protocol was modified for the equine
sera samples.
Solutions prepared included 5% ACN/0.1% formic acid/waterb (equilibration/wash
solution), 70% methanol/0.1% formic acid/waterb (elution solution), 10% formic acid, and
1% formic acid. 100% formic acid was serially diluted to achieve required concentrations.
The equilibration/wash solution and elution solution were then prepared in the appropriate
volumes. Falcon tubes were placed into a vacuum manifoldk. The columns were
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conditioned twice with 1 mL of methanol, utilizing the vacuum to pull the methanol
through each time. Next, the columns were equilibrated once with 1 mL of
equilibration/wash solution, which was pulled through using the vacuum. Samples were
thawed, centrifugedh, and the total volume was applied to the column, and pulled through
into the Falcon tube using the vacuum. The column was then washed twice with 1 mL of
equilibration/wash solution, pulling the contents through the column each time. Digests
were eluted from columns by applying 500 mL of elution solution two times, pulling the
solution through each time. Falcon tubes containing eluted digests were briefly spun down
to collect eluant. The eluants were then transferred to a 1.5 mL Eppendorf tube. The
samples were dried down under centrifugal evaporation in the Savant SpeedVac SPD 1030
Integrated Vacuum Chamberf.
2.2.3 Mass Spectrometry Injection
For LC-MS/MS injection, the resulting protein in the samples must be resuspended.
This resuspension allows for a total of 10 µg of protein in digest. The resuspension buffer
was 5% ACN, 0.1% formic acid, and double-distilled waterb. The dried down samples were
resuspended in 100 µL of buffer and vortexedl thoroughly to mix. They were then pulse
centrifugedh to ensure all the components were removed from the side of the tube. SureStop
MS injection vials were labeled, and glass inserts were placed inside. Thirty µL of the
reconstituted digest was transferred into the glass insert and these were then placed in the
LC-MS/MS instrument for duplicate 10 µL injections. Digested peptides were
chromatographically separated using the UltiMate 3000RSLC nano liquid chromatography
systemj. This system is equipped with an Easy Spray PepMapTM RSLC C18 columnc (3
µm, 100Å, 75 µm x 15 cm) and an AcclaimTM PepMapTM trap columna (3 µm, 0.075 mm
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x 20 mm) set at 35⁰C. There were two mobile phases, A and B. Mobile phase A contained
0.1% (v/v) formic acid in waterb while mobile phase B contained 0.1% (v/v) formic acid
in acetonitrile. A linear gradient of 5-31% mobile phase B over 85 minutes at a flow rate
of 0.3 µL/minute was used for peptide separation. Data-dependent acquisitions (DDA)
were performed on a OrbitrapTM Exploris 480 mass spectrometerd. The instrument was
operated in positive ion mode using a top-20 method.
To acquire survey scan mass spectra (350-1200 m/z), a nominal resolution of 60,000
FWHM and a normalized target of 300% were utilized. Acquisition of fragmentation
spectra was completed using a nominal resolution of 15,000 FWHM with a normalized
collision energy of 30% and dynamic exclusion of 20 seconds, normalized automatic gain
control (AGC) target of 50%, maximum injection time of 50 ms, and isolation window of
1.4 m/z. The electrospray ionization settings included a spray voltage of 2500 V, capillary
temperature of 275⁰C, and an RF lens value set at 40%. No sheath, auxiliary, or sweep gas
were applied.
2.2.4

Label-Free Quantitation and Data Analysis

Once the samples were finished running on the OrbitrapTM mass spectrometerd, the
acquired mass spectra data were analyzed using PD 2.4e. Protein identification and labelfree quantitation was performed against the Equus callabus database, downloaded from
Uniprot (17 March 2021).
Using custom built processing and consensus workflows, the acquired data were
analyzed. Processing workflows included two iterative searches using SequestHT,
Percolator validation, and Minora Feature Detector. Basic search settings utilized in the
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first iterative search included static modification of carbamidomethylation (+57.021 Da);
a precursor mass tolerance of 10 ppm; a fragment mass tolerance of 0.02 Da; a maximum
of two miscleavages; a dynamic modification of oxidation (+15.999 Da); protein Nterminal modifications of acetylation (+42.011 Da), methionine loss (-131.010 Da), and
methionine loss plus acetylation (-89.030 Da). The second iteration searched for any
additional peptide modifications.
The role of the consensus workflow was to filter for high confidence peptides with
enhanced protein and peptide annotations. The confidence thresholds were determined by
target false discovery rates (FDRs) of 0.01 (strict) and 0.05 (relaxed). An FDR is the ratio
between false peptide spectra matches (PSM) to the total number of PSMs above the score
threshold, or the measure of the incorrect PSMs among all accepted PSMs. The strict FDR
is set for highly confident PSMs, while the relaxed FDR is for PSMs with medium to low
confidence. Quantitation was performed using unique and razor peptide classification(s).
The protein grouping strict parsimony principle was set to true.
The individual horse and its corresponding time points were analyzed as biological
replicates to identify any changes (upregulation or downregulation) to protein abundances
during the sampled time course. This was repeated for all 19 horses. The workflow
executed analyses on these changes and allowed for the visualization of the data through
graphs and tables generated in Microsoft 365 Excel (Version 2201) and SigmaPlot
(Version 14.5). PD 2.4e data was used to produce a heat map that portrayed the changes in
the four identified biomarkers across the full-time course. This software and the data it
generated also allowed for the determination of percent differences in abundances of the
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four proteins compared to their abundance at day 0. Abundance at day 0 was calculated by
averaging the five horses who were sampled at day 0 for each protein.

2.3

Results
Through label-free quantitation (LFQ), a total of 19 proteins were identified that were

postulated as relevant to bisphosphonate administration (Table 2-2). Out of these, four key
proteins were focused on: actin (cytoplasmic), carbonic anhydrase, fibrinogen, and
fibronectin. Each of these proteins had abundance patterns that were easily identified after
performing custom-built workflows. While no significance tests were performed, clear,
measurable trends were observed in each of the four protein biomarkers and will be
discussed in the following paragraphs. All upregulation and downregulation patterns are
those in comparison to previous days’ abundances. For example, upregulation at day 7
indicates an increase in abundance when compared to day 3, and a downregulation at day
18 indicates a decrease in abundance when compared to day 7.
Actin (cytoplasmic) exhibited an abundance pattern of upregulation at day 7,
downregulation at day 18, and upregulation at the next time point, depending on the horse
and whether it was sampled on these particular days. This pattern was observed in five
horses with relevant time points. For four other horses, there was an abundance pattern of
upregulation at day 49. These patterns can be seen in Figure 2-1A, Figure 2-2A, and
Figure 2-3. By using custom built workflows, PD 2.4e was able to find high confidence
peptides for actin. Fragmentation spectra for two of these high confidence peptides can be
found in Figure 2-4A. These are both exemplar spectra for this protein and are
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representative of MS2 fragmentation patterns. They are from the same time point in the
same horse.
Carbonic anhydrase exhibited an abundance pattern similar to that of actin. Five
horses showed upregulation at day 7, downregulation at day 18, and upregulation at the
next time point. Three horses had an upregulation of carbonic anhydrase at day 49. These
patterns can be seen in Figure 2-1B, Figure 2-2B, and Figure 2-3. PD 2.4e refined peptides
to those with high confidence that identified carbonic anhydrase. Two high confidence
peptides’ fragmentation spectra can be found in Figure 2-4B. These spectra were chosen
based on how well they represent MS2 fragmentation. They are from the same time point
in the same horse.
Fibrinogen presented the same abundance pattern as the previous two proteins. Five
horses showed an upregulation at day 7, downregulation at day 18, and an upregulation at
the next time point. Three horses exhibited an upregulation day 49. Abundance patterns are
presented in Figure 2-1C, Figure 2-2C, and Figure 2-3. Fibrinogen’s high confidence
peptides were chosen in PD 2.4e using iterative searches and custom-built workflows. In
Figure 2-4C, fragmentation spectra of two of these peptides are depicted and are
representative of MS2 fragmentation. Both spectra are from the same time point in the
same horse.
Fibronectin, the final protein identified, displayed an opposite trend compared to the
first three identified proteins. Six horses showed a downregulation at day 7 and five of
those horses showed a subsequent upregulation at day 18 (due to relevant time points).
These patterns are shown in Figure 2-1D, Figure 2-2D, and Figure 2-3. Figure 2-3 is
meant to compare the abundances at each time point to the abundance at day 0. For
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fibronectin, this table shows a downregulation at day 0, and this was taken into
consideration when analyzing the heat map. It still depicts a downregulation at day 7 and
day 21 in comparison to the upregulation seen at day 18, however, the downregulations are
not depicted in red due to day 0 showing a downregulation. Day 7 and day 21 show a slight
upregulation in comparison to day 0 but are still downregulated in comparison with day
18. Fibronectin fragmentation spectra are shown in Figure 2-4D. These spectra represent
two of the several high confidence peptides that were found in PD 2.4e. They are
characteristic of MS2 fragmentation data and are exemplar spectra for this protein.
Average abundances of the four proteins in the master horse can be found in Table
2-3. These abundances, for the most part, are higher than those found in Figure 2-1 A-D
and are represented by the dotted line present on each graph. Carbonic anhydrase is the
only protein where the majority of abundances are upregulated compared to the average
abundance of carbonic anhydrase in the master horse sera.

2.4

Discussion
The four identified proteins and their individual abundance patterns are postulated to

have some relevance to the administration of bisphosphonates. Actin and carbonic
anhydrase are both found in osteoclasts and aid in their ability to resorb bone. There is
evidence that shows fibrinogen is located on the surface of osteoclasts (Athanasou et al.,
1988). Fibronectin is deposited from osteoblasts for the purposes of ossification. These
proteins were changed early in comparison to the known maximum efficacy of
bisphosphonates at sixty days. However, because the bisphosphonate was administered to
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the equine subjects intravenously rather than orally, it is possible that the maximum
resorption suppression took place earlier (Drake et al., 2008).
The type of actin identified is beta-actin, which can be found in several different types
of cells within the horse. Beta-actin is important in cell motility and migration in all cells
of the body (Bunnell et al., 2011). As osteoclasts begin to resorb bone, they must degrade
the bone matrix. To do this, they form a complex that consists of a ruffled border and actin
rings; the actin rings will form podosomes that evolve into the osteoclast sealing zone,
facilitating bone resorption (Han et al., 2019). Podosomes are found to have a dense core
of actin, while also consisting of other proteins like integrins (Destaing et al., 2003). The
actin rings are unique to osteoclasts, since most other cells arrange their fibrillar actin into
stress fibers (Teitelbaum, 2007). Actin’s abundance pattern shows an initial upregulation
at day 7. This increase is postulated to be the result of an osteoclast receiving a signal to
begin resorbing bone. The osteoclasts, in order to facilitate resorption, must utilize actin to
create podosomes and, in turn, the sealing zone that is integral to making contact with the
bone matrix. This would, in theory, cause an upregulation in the concentration of actin.
The goal of bisphosphonates is to reduce bone resorption by targeting osteoclasts. At day
18, there is a downregulation in the concentration of actin. Bisphosphonates accumulate in
the bone and become active when bone resorption occurs, thereby releasing them (Lin,
1996). At day 7, when the osteoclast received the signal to begin bone resorption, it
increased its actin to facilitate the degradation of the bone matrix, which resulted in the
release of the bisphosphonates that had been previously administered. The bisphosphonate,
once released, becomes active and causes apoptosis of the osteoclast by blocking its ATPdependent pathways, resulting in a decrease in actin abundance seen at day 18. It is
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important to keep in mind that because actin is located inside the osteoclast, apoptosis, and
therefore lysis of the cell, may cause transitory changes in the abundance of actin.
Furthermore, bone resorption requires acidification of the bone matrix. This is
enabled by carbonic anhydrase II (CA II), an enzyme that produces protons from the
conversion of carbon dioxide into bicarbonate (Riihonen et al., 2007). CA II can be found
in erythrocytes, as well as the large intestine in horses (Sasaki et al., 1993). It has been
shown in vivo that mutation of the CA II gene can lead to osteopetrosis, a disease that
results from the inhibition of bone resorption, meaning that this enzyme is also found in
bone (Lehenkari et al., 1998). This enzyme, therefore, is likely upregulated when
osteoclasts begin resorbing bone since its activity is necessary for the initial degradation of
the bone matrix. It is postulated that the initial upregulation in carbonic anhydrase
abundance is due to the activation of osteoclastic activity. Again, since bisphosphonates
are released from the bone and subsequently activated after osteoclasts begin resorption, it
is likely that the apoptosis of the osteoclast resulted in a downregulation of carbonic
anhydrase—an enzyme that would not be needed if osteoclastic resorption is not actively
occurring.
Fibrinogen is a protein that is typically involved in blood coagulation and is cleaved
by thrombin resulting in fibrin protein (Almeida et al., 2020). This protein has also been
observed to increase somewhat within 72 hours following inflammation (Copas et al.,
2013). There has been evidence that shows fibrinogen binding to the surface of osteoclasts,
although the exact reason for this is unknown (Athanasou et al., 1988). Through a study
assessing the main function of plasmin as it relates to bone biology, it was demonstrated
that fibrinogen is an exogenous activator of the bone remodeling unit, namely bone
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resorption (Cole et al., 2014). This protein presented an abundance pattern of upregulation
at day 7 and downregulation at day 18. Since the osteoclast likely received a signal at day
7 to begin resorbing bone, its activity presented as an increase in fibrinogen, while the
apoptosis that followed was conveyed as a decrease in fibrinogen at day 18.
The final protein identified, fibronectin, displayed an abundance pattern that was the
opposite of the previous three proteins, as previously mentioned. Fibronectin is a protein
that is found in the bone matrix, but it also acts as the master organizer of extracellular
matrix assembly in all cell types (Halper and Kjaer, 2014). Studies have shown that the
presence of fibronectin is necessary for the initial assembly of the collagen matrix in bone,
but it is also needed continuously to ensure the integrity of the bone matrix (Bentmann et
al., 2010). This protein is the earliest protein synthesized by osteoblasts for the bone matrix
(Tang et al., 2004). Bone remodeling requires a tightly regulated balance between
osteogenesis (performed by osteoblasts) and osteolysis (performed by osteoclasts) to
ensure tissue homeostasis (Cole et al., 2014). It was previously postulated that the
upregulation of actin, carbonic anhydrase, and fibrinogen at day 7 and downregulation at
day 18 was the result of initial osteoclast-mediated bone resorption followed by a
bisphosphonate-mediated decrease in osteolysis activity. Because bone cells and their
subsequent actions are tightly regulated, an osteoblast would be turned off when osteoclasts
are signaled to resorb bone, and then turned on once the osteoclast completes resorption or
goes through apoptosis. At day 7, it can be suggested that the osteoclastic activity
suppressed the activity of the osteoblast, meaning no fibronectin was being deposited to
begin generation of new bone, resulting in a downregulation of fibronectin abundance at
this time point. Once the bisphosphonate blocked osteoclast ATP-dependent pathways and
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caused apoptosis of the bone resorbing cell, the osteoblast likely received a signal to begin
laying down new bone. This process would have caused an increase in fibronectin, at least
initially (Bentmann et al., 2010). An upregulation of fibronectin is seen at day 18.
The master horse represents a control in that it depicts basal levels of the four key
protein biomarkers in a normal horse. The overall downregulation in each protein
compared to the average abundance in the master horse sera can be attributed to the fact
that the 19 equine subjects in this study were experiencing a symptomatic disease that
required some intervention. The master horse sera are representative of horses that are
presumed to be normal and not suffering from any type of disease. Day 0 of the blood
samples represented a control, also, since no drug had been administered at that point.
Ratios of the identified biomarker abundances at each time point with the abundance at day
0 can be found in Table 2-3 and Figure 2-2 A-D.
Because these proteins are not specific to the bone remodeling process, they can be
found in other areas of the biological system. Variability of these biomarkers and their
different locations in the horse are discussed in Chapter 3 Section 3.5. Limitations of the
discovery and targeted based portions of this study are located at the end of Chapter 3 in
Section 3.6.

2.5

Conclusion
The discovery phase of this study identified four protein biomarkers that were

hypothesized to change in response to bisphosphonate administration. The natural variation
of time points made it somewhat difficult to compare all 19 horses, but there were distinct
abundance patterns found in each of the four proteins in almost all subjects. Actin, a protein
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found in the podosomes of osteoclasts once they begin resorbing bone, conveyed changes
in concentration at day 7, day 18, day 21, day 28, and day 49. These changes were likely
due to normal remodeling processes being interrupted by the administration of the antiresorptive agent, tiludronate. Carbonic anhydrase, an enzyme responsible for the
acidification of the bone matrix during remodeling, experienced distinct abundance pattern
alterations at day 7, day 18, day 21, day 28, and day 49. Because this enzyme is crucial to
osteoclastic activity, those upregulations and downregulations were likely due to the
bisphosphonate that was initially administered. Fibrinogen, a protein postulated to be an
exogenous activator of bone resorption and found on the surface of osteoclasts, exhibited
changes in abundance at day 7, day 18, day 21, day 28, and day 49. Because fibrinogen is
found on osteoclasts, it may have been upregulated and downregulated at the same time as
the osteoclast. The goal of the bisphosphonate is to cause apoptosis of the osteoclast, which,
in turn, causes changes in the concentrations of fibrinogen. Finally, fibronectin is a protein
found in the bone matrix and synthesized by osteoblasts, had an abundance pattern opposite
of the previous three proteins, with changes being exhibited at day 7, day 18, day 21, day
28, and day 49. Because this protein’s goal is opposite of the osteoclast, it was likely
upregulated when osteoclastic proteins were downregulated, and vice versa.
Each of these protein biomarkers can be traced back to bone remodeling and
bisphosphonate administration in some way. The equine subjects were in training at the
time tiludronate was given and when blood samples were taken across the various time
points. Because horses in training experience continuous remodeling, especially in high
load environments, the initial upregulations in abundance of the first three proteins that are
seen at day 7 may have been due to their rigorous training regimens. However,
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bisphosphonates’ goal is to suppress normal remodeling by inhibiting resorption and
increasing the viability of osteoblasts to complete ossification. So, the subsequent
downregulation seen in osteoclastic proteins is likely a result of bisphosphonate action on
the osteoclast. The upregulation of fibronectin, the osteoblastic protein, was presented at
the same time as the downregulation of the proteins in the osteoclast, which may be a
display of increased viability of the osteoblast due to the administration of tiludronate.
Further confirmation that these proteins are changed in response to bisphosphonate
administration and have some significance to bone remodeling can be seen by the
differences in abundance between the 19 equine subjects and the master horse sera. The
proteins’ abundances are decreased in the equine subjects in this study compared to their
average abundance in a master horse serum sample, seen in Table 2-3 and Figure 2-1 AD. The horses in this study were affected by some disease and were administered
bisphosphonates as treatment. It is likely that the abundances of the four key protein
biomarkers will be changed in a treated horse in comparison with a normal horse.
These biomarkers, after further validation in the targeted phase, will be integrated
into the Equine Biological Passport to create a way to identify the restricted use of
bisphosphonates during a race across a longer detection window. The four key proteins
identified represent a way to help protect the integrity of the racing industry, as well as the
welfare of horses.
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TABLES
Table 2-1: Monitored Time Courses of 19 Horses Following Tildren® Administration1

1

19 equine subjects and what days blood samples were taken from them.
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Table 2-2: 19 Proteins Identified Through Label-Free Quantitation2

Protein

Accession No.

Actin beta like 2

F7AHF3

Actin gamma 2, smooth muscle

A0A3Q2HBP5;
A0A3Q2KTQ9

Actin, cytoplasmic 1

A0A3Q2KTQ9

Carbonic anhydrase

A0A3Q2HMG5;
F6ZBG0

EGF containing fibulin extracellular
matrix protein 1

F6PVG3

Elongation factor 1-alpha

F6UME7

Extracellular matrix protein 1

F6QYS3

Fibrinogen

A0A3Q2GS38

Fibrinogen alpha chain

A0A3Q2HTG2;

Fibrinogen gamma chain

A0A5F5PPB8

Fibrinogen beta chain

F6PH38

Fibronectin

A0A5F5PTE1;
F7CN11; Q28377

Fibulin 1

F7ABC9

Intercellular adhesion molecule 3

F6SIE2

Interleukin 1 receptor accessory
protein

A0A5F5PI46

Matrix metallopeptidase 19

F7C6S0

Talin 1

F6QIZ4

Transforming growth factor-betainduced protein ig-h2

F6UMQ4

Vitronectin

F6V881

2

The 19 proteins that were identified from the data through LFQ that showed some
significant abundance pattern. Highlighted are the proteins and accessions of the four key
proteins identified in the discovery phase.
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Table 2-3: Master Horse Sera Average Abundance of Four Key Protein Biomarkers3

Accession
Description
Average Abundance Std Deviation
A0A3Q2KTQ9 Actin, cytoplasmic 1 OS=Equus caballus OX=9796 GN=ACTB PE=3 SV=2
1.03E+07
2.46E+06
F6ZBG0
Carbonic anhydrase OS=Equus caballus OX=9796 GN=CA1 PE=3 SV=1
1.47E+06
5.66E+05
A0A3Q2HTG2 Fibrinogen alpha chain OS=Equus caballus OX=9796 GN=FGA PE=4 SV=2
3.62E+06
6.58E+05
F7CN11
Fibronectin OS=Equus caballus OX=9796 GN=FN1 PE=4 SV=2
3.21E+07
7.12E+06

Std Error
9.30E+05
2.14E+05
2.49E+05
2.69E+06
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The average abundances of actin, carbonic anhydrase, fibrinogen, and fibronectin in a master horse sera sample
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Figure 2-1 A-D: Global Discovery Figure of Relative Abundances of Four Key Proteins
Identified with Master Horse Sera Average Abundance.
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Figure 2-1: Master horse sera average abundance is represented as a dotted line. (A)
The abundance patterns of the protein actin from day 0 to day 62. This constitutes each
horse and the standard error are shown. The dotted line represents average abundance
of actin observed in master horse sera. (B) The abundance patterns of carbonic
anhydrase of each horse that is represented at each time point, as well as the standard
error. Master horse sera average abundance of carbonic anhydrase is represented by the
dotted line. (C) The abundance patterns of fibrinogen from day 0 to day 62. This
constitutes each horse and the standard error is shown. The dotted line represents
average abundance of fibrinogen observed in master horse sera. (D) The abundance
patterns of fibronectin of each horse that is represented at each time point, as well as the
standard error. Master horse sera average abundance of fibronectin is represented by the
dotted line.
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Figure 2-2 A-D: Ratio Differences of Four Key Proteins Compared to Day 0 Abundance.
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Figure 2-2: (A) This graph is meant to compare the abundance pattern of actin at each
time point with the abundance at day 0. The bars that fall below the central line represent
downregulation in comparison to day 0 abundance and the bars that fall above the central
line represent upregulation in comparison to day 0 abundance. (B) The abundance pattern
of carbonic anhydrase compared to the abundance at day 0. (C) Fibrinogen’s abundance
pattern in comparison to the abundance at day 0. (D) The abundance pattern of fibronectin
as compared to day 0 abundance.
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Figure 2-3: Heat Map of Abundance Patterns Compared to Day 0.
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Figure 2-3: A heat map of the four key protein biomarkers from day 0 to day 62. Red represents downregulation in comparison to the
abundance at day 0 and green represents upregulation in comparison to the abundance at day 0. Actin, carbonic anhydrase, and fibrinogen
all exhibit an upregulation at day 7 and day 21, and a downregulation at day 18. Fibronectin, similar to Figure 2-2D, shows no
downregulation except at day 0. However, the abundances at day 7 and day 21, where there should be downregulation, show a color that
is closer to white, which represents a downregulation from the abundance seen at day 18.
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Figure 2-4 A-D: Peptide Fragmentation Spectra.
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Figure 2-4: (A) Peptide fragmentation spectra of actin. Each of these spectra are from the same time
point in the same horse and were chosen because they are high confidence peptides. These spectra
also represent ms2 fragmentation well. This figure depicts good fragmentation patterns for the primary
accession of actin. Included in this figure is the peptide that is represented in the fragmentation spectra.
(B) Peptide fragmentation spectra of carbonic anhydrase. Two high confidence peptides are
represented, and each spectrum is from the same time point in the same horse. The spectra portray
quality patterns of fragmentation for carbonic anhydrase’s primary accession. Included in this figure
is the peptide that is represented in the fragmentation spectra. (C) Peptide fragmentation spectra of
fibrinogen. Each spectrum was chosen based on acceptable fragmentation patterns of the primary
accession of fibrinogen, as well as good ms2 fragmentation representation. The spectra are from the
same time point in the same horse. Included in this figure is the peptide that is represented in the
fragmentation spectra. (D) Peptide fragmentation spectra of fibronectin. Two high confidence
peptides were chosen based on how well they represented ms2 fragmentation and the quality of their
fragmentation patterns. The spectra are from the same time point in the same horse. Included in this
figure is the peptide that is represented in the fragmentation spectra.
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Figure 2-5: Actin Protein Sequence.
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Figure 2-5: The protein sequence of the primary accession of actin. The amino acid
sequences that are highlighted within the main sequence are the peptides used by PD 2.4e for
LFQ.
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Figure 2-6: Carbonic Anhydrase Protein Sequence.
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Figure 2-6: The protein sequence of carbonic anhydrase. This sequence represents the main
accession used for data analysis. The highlighted portions are those used by PD 2.4e for LFQ.
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Figure 2-7: Fibrinogen Protein Sequence.
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Figure 2-7: The main accession protein sequence of fibrinogen. The small sequences
that are highlighted represent the peptides used by PD 2.4e for LFQ.
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Figure 2-8: Fibronectin Protein Sequence.
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Figure 2-8: Fibronectin’s main accession protein sequence is depicted in this figure. The
highlighted sequences are peptides that were used for LFQ within PD 2.4e.
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CHAPTER 3. VERIFICATION OF IDENTIFIED BISPHOSPHONATE PROTEIN BIOMARKERS
USING A MASS SPECTROMETRY TARGETED METHOD
3.1

Introduction
Bisphosphonates are anti-resorptive drugs that are used for treatment of diseases in

humans and animals. Once administered either intravenously or intramuscularly into the
horse, the drug travels through the bloodstream and deposits into areas of the skeleton that
have the highest turnover rates, resulting in a heterogenous deposition (Soares et al., 2016).
The proportion of drug that is not incorporated into bone is rapidly excreted through the
urine without being metabolized (Reszka and Rodan, 2003). Because of this, a targeted
method must be developed to identify and validate any proteins that may be changed in
response to the administration of bisphosphonates. These proteins will be considered
biomarkers that can aid in the identification of prohibited substances during horse racing.
There are several different targeted techniques that can be used to validate the
biomarkers that were identified in the discovery phase. SRM, MRM, and PRM are targeted
methods that are widely used in proteomics. SRM is a technique that was used in the
beginning of targeted proteomics that only allowed the monitoring of one transition at a
time. MRM is a technique that gained popularity when the capacity of instruments to
perform workflows increased. This targeted method, sometimes referred to as selected
reaction monitoring, is utilized for the quantification of analytes that are predetermined and
have known fragmentation properties (Abbatiello et al., 2010; Lange et al., 2008). Used on
its optimal instrument, a triple quadrupole mass spectrometer, which can act as a mass
filter, MRM can monitor specific analytes and their subsequent fragment ions; the pair that
consists of analyte and fragment ion is known as a transition (Picotti and Aebersold, 2012).
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This targeted technique can quickly measure the transitions and allow for simultaneous
analysis of analytes—a step up from the single transition that SRM could monitor (Picotti
and Aebersold, 2012). PRM, the targeted technique used in this study, has been shown to
result in a wider range of quantitative data than MRM against a complex background
(Peterson et al., 2012). Unlike MRM, PRM does not require pre-selection of transitions,
making it easier to develop a method (Rauniyar and Keck, 2015). Another advantage that
PRM has over MRM is the availability of all product ions in a single analysis to confirm
the peptide’s identity, rather than only three to five selected transitions that can be
monitored using MRM (Peterson et al., 2012). There have been studies that show PRM and
MRM exhibit similar linearity, precision, and repeatability of protein quantification in high
density lipoprotein; however, because PRM requires less method development and has the
potential to be more specific than MRM, PRM is the preferred technique of a targeted phase
(Ronsein et al., 2015). PRM data was analyzed using Skylineg software. This software is
an application popularly used in targeted proteomics and was selected for this study due to
its simplicity of method development, sharing ability, and the way it displays results clearly
and efficiently (MacLean et al., 2010).
The four proteins identified in the discovery phase—actin, carbonic anhydrase,
fibrinogen, and fibronectin—were validated using PRM for the targeted phase of this study.
While these proteins are involved in bone remodeling, they are not specific to the process.
However, their abundance changes at the same time points in several of the horses suggest
a link to bisphosphonate administration.
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3.2

Materials and Methods
3.2.1

Sample Preparation

Samples from each horse and each time point (n = 79) were fractionated,
enzymatically digested, and de-salted in duplicate, as previously described in Chapter 2.
The duplicate biological samples were injected into the Orbitrap™ mass spectrometerd in
duplicate.
3.2.1.1 Organic Solvent Fractionation
The goal of organic solvent fractionation is to remove the abundant and complex
protein albumin from the samples to increase detection of relevant peptides on the mass
spectrometerd. The protocol for IPA-TCA fractionation developed and optimized by Liu et
al. which was used in the discovery phase of this study, seen in the Materials and Methods
section of Chapter 2, is also used in the targeted phase (Liu et al., 2014).
3.2.1.2 Tryptic Digestion
To assess the peptides of the four biomarkers through a PRM method, trypsin was
used as it was in the discovery phase to digest the proteins into peptides. These can be
reconstructed after mass spectrometric injection to analyze the proteins of interest. Trypsin
is a popular enzyme for this step in discovery and targeted phases due to its inexpensiveness
and effectiveness when digesting proteins (Gillet et al., 2016). The protocol found in the
Materials and Methods section of Chapter 2 is unchanged in the targeted phase.
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3.2.1.3 Strata Column Clean-Up
The final step before instrument injection is clean-up. This procedure is important to
ensure the quality of peptides being injected and analyzed. Its role is to remove
contaminants, like natural salts, that may be present on the peptide, while ensuring that the
peptide itself is eluted from the C18 size Strata-X SPE column. The protocol from the
manufacturer of Strata-X SPE columns (Phenomenex) was modified for the equine sera
samples in the Chapter 2 Materials and Methods section and is used in this phase, as well.
3.2.2 Mass Spectrometry Injection
LC-MS/MS injection requires the digested protein to be resuspended in 5% ACN,
0.1% formic acid, and double-distilled waterb for a total of 10 µg of protein in digest. The
resuspension buffer was prepared the same as the buffer in the discovery phase, for which
the protocol can be found in the Chapter 2 Materials and Methods section. Samples were
resuspended in 100 µL of buffer and SureStop MS injection vials were utilized in this
phase, as well. Once samples were prepared and placed in the Orbitrap™ mass
spectrometerd, they were queued for duplicate 10 µL injections for analysis. A PRM
method was developed for the targeted phase based on the untargeted data where four
proteins of interest were identified. This method was used to analyze digested proteins on
an OrbitrapTM Exploris 480 mass spectrometerd coupled with an UltiMate 3000
RSLCnanoj.
Specifications for chromatographic separation in the targeted phase were similar to
those used in the discovery phase. Digested peptides were chromatographically separated
using the UltiMate 3000 RSLCnano liquid chromatography systemj. The specifications for
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the Easy Spray PepMapTM RSLC C18 trap columnc are unchanged from the Materials and
Methods section of Chapter 2. There were two mobile phases: mobile phases A and B. The
column was equilibrated for 7 minutes at 2% mobile phase B. The gradient was ramped to
10% mobile phase B from 7-10 minutes. A linear gradient from 10% to 25% mobile phase
B, occurred over 25 minutes. A second linear gradient from 25% to 55% mobile phase B
over 4 minutes, followed by 98% mobile phase B over one minute. Mobile phase B was
maintained at 98% for 5 minutes followed by re-equilibration at 2% mobile phase B for 5
minutes. The total chromatographic run time was 50 minutes.
The instrument was operated in positive ion (+) mode using a targeted mass spectra
(tMS2) methodology. To obtain tMS2, an inclusion list of relevant peptides selected from
the discovery data acquisitions, described previously in chapter 2, were utilized. The
inclusion list consisted of peptide sequence, retention times, m/z values, and peptides
charge state. A nominal Exploris 480™ resolution of 60,000 FWHM and a normalized
target of 300% were utilized. The normalized higher energy C-trap dissociation (HCD)
collision energy was 30% and dynamic exclusion was 20 seconds. A standard AGC target,
maximum injection time of 200 ms, and isolation window of 1.6 m/z were utilized. The
electrospray ionization settings for spray voltage, capillary temperature, and RF lens value
are unchanged from Chapter 2. As in the discovery phase in Chapter 2, no sheath, auxiliary,
or sweep gas were applied.
3.2.3

Label-Free Quantitation and Data Analysis

Data obtained from the Exploris 480™ mass spectrometerd were analyzed using
Skylineg software. For each of the four identified protein biomarkers, the optimal peptides
and transitions were selected based on data gathered initially in the discovery and targeted
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phases. Using Skylineg software and iterative targeted PRM acquisitions to obtain the most
favorable peptides and transitions, 103 peptides were refined down to 23 unique peptides
based on retention time, fragment ion ppm tolerance (±10 ppm), and number of detectable
transitions. These unique peptides were also chosen based on their peak area and
proteotypic properties (i.e., being truly tryptic). The refinement process removed peptides
that had poor peak shape and area and were undetectable from the background matrix.
Detection of ions and peptides is greatly affected by the complexity of the sera background.
The 23 unique peptides, as well as their m/z ratios and retention times, can be seen in Table
3-1.
Semi-quantitative analyses that were performed using PRM methodology and the top
three most abundant peptides for each identified biomarker were determined. The percent
differences from day 0 were determined for each time point from day 1 to day 62.

3.3

Results
Refinement of the 103 initial peptides resulted in 23 unique peptides for all four

proteins. Actin had four unique peptides, carbonic anhydrase had three unique peptides,
fibrinogen had five, and fibronectin had eleven. The top five to six transitions for each
peptide were included in the data analysis. In Skylineg, each protein exhibited the same
trends that were seen in the discovery phase of this study in both replicates that were
analyzed. In the following paragraphs, observations made based on targeted PRM data for
each replicate analyzed will be discussed. All upregulation and downregulation patterns
are observed the same way as they were in the discovery phase. An upregulation on a
certain day indicates an abundance increase when compared to the previous time point,
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while downregulation is indicative of an abundance decrease compared to the previous
time point. No significance tests were performed, and observed trends are from clear,
measurable patterns.
Actin was upregulated at day 7, downregulated at day 18, and upregulated at day
21, day 28, day 42, or day 49 depending on the horse and what days it was sampled. This
was true for all four peptides in both replicate one and replicate two. For horses with the
relevant time points, the abundance of actin was also upregulated at day 57 and
downregulated at day 62 for all four peptides in both replicates. The average of the top
three most abundant peptides for actin was used to determine the percent difference from
day 0 for each time point. Days 1, 3, 18, 34, 42, 57, and 62 were all downregulated in
comparison with day 0. Day 18 was downregulated at a 164% difference from day 0. Day
62 was downregulated at 131%. Day 7 exhibited an upregulation of 37% compared to day
0. These patterns can be seen in Figure 3-1A. The abundance patterns of actin are also
represented in Figure 3-2A. Upregulation is exhibited on day 7, while day 18 is
downregulated. There is also a clear upregulation on day 21. The standard error (SE) is
also presented on this graph but is not visible because of its very small variance, indicating
that the abundances are precise in representing the population. Actin’s abundance patterns
can also be viewed in the peak area graph created in Skyline software, shown in Figure 33A. This graph only shows one replicate, but duplicate samples are shown for each time
point.
In replicate one, carbonic anhydrase exhibited upregulation at day 7,
downregulation at day 18, and, depending on the horse, upregulation at day 21, day 28, day
42, or day 49 in two of the three unique peptides. In the third peptide, the protein still
68

showed an upregulation at day 7 and downregulation at day 18, but days 21, 28, 42, and 49
were at too low of an abundance to determine upregulation or downregulation. In replicate
two, carbonic anhydrase was upregulated at day 7, downregulated at day 18, and
upregulated on days 21, 28, 42, and 49 for all three peptides. In replicates one and two, this
biomarker was upregulated at day 57 and downregulated at day 62 in all six horses with
relevant time points in peptide one. In peptide two, the abundances were too low to confirm
a pattern at these time points in any of the six relevant horses. In replicate one, peptide
three showed this abundance pattern in two of the six relevant horses. In replicate two,
peptide three showed this abundance pattern in all six relevant horses. Carbonic anhydrase,
in comparison to day 0, exhibited downregulation on days 1, 3, 18, 34, 42, 49, 57, and 62.
Day 1 was downregulated at 157% compared to day 0. Day 18 was downregulated at 110%,
day 57 was downregulated at 128%, and day 62 was downregulated at 159% when
compared with day 0. Carbonic anhydrase displayed an upregulation in abundance
compared with day 0 on days 7, 21, 28, and 31. Day 7 was upregulated at 96%. This can
be seen in Figure 3-1B. In Figure 3-2B, carbonic anhydrase upregulation and
downregulation is shown on days 7 and 18. Days 28, 31, 34, 42, and 49 are all upregulated
in comparison to day 18, as well. The SE was also calculated for the abundance data at
each time point and is shown here, however, it is not visible due to its small variance,
indicating precision in representation of the population. Carbonic anhydrase’s distinct
abundance patterns can be seen in the peak area graph created in Skyline in Figure 3-3B.
In replicate one, fibrinogen displayed an abundance pattern of upregulation at day
7 and downregulation at day 18 in four of the five selected peptides. In peptides two and
three, three out of five horses with these time points exhibited this pattern. In peptides four
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and five, four of the five horses with relevant time points showed this abundance pattern.
None of the five relevant horses for peptide one displayed this pattern. In replicate two,
fibrinogen exhibited upregulation at day 7 and downregulation at day 18 in all five selected
peptides. Peptide one contained one horse out of the five relevant horses that displayed this
pattern. Peptides two and three had three out of the five horses with these time points that
exhibited this abundance pattern. Peptides four and five showed this pattern in four out of
the five relevant horses. Fibrinogen, in comparison with day 0, exhibited downregulation
on days 1, 3, 18, 34, 42, 49, 57, and 62. Day 18 showed a 102% downregulation compared
to day 0. This biomarker also conveyed an upregulation in abundance compared to day 0
on days 7, 21, and 31. Day 7 exhibited a 67% upregulation difference. Figure 3-1C
conveys these abundance patterns. Fibrinogen, in Figure 3-2C, is upregulated on day 7
and downregulated on day 18. Days 21, 28, 31, 34, 42, and 49 are upregulated, as well, in
comparison to day 18. The SE for abundance at each time point was calculated and is
represented in this graph. Because of the extremely small variance of SE, it cannot be seen
at any time point. Fibrinogen’s abundance patterns on days 7 and 18 can also be seen in
the peak area graph created in Skyline in Figure 3-3C.
Fibronectin was identified in the discovery phase to have the opposite pattern as
the other three biomarkers of downregulation at day 7 and upregulation at day 18. In
replicate one, one of the eleven peptides only had one horse that displayed this pattern, out
of the five that were sampled on days 7 and 18. Three of the eleven peptides contained
three horses out of the five that exhibited this pattern. Seven of the eleven peptides showed
four of the five relevant horses that displayed this abundance pattern. In replicate two, five
of the eleven peptides had three horses that exhibited downregulation at day 7 and
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upregulation at day 18. Three of the eleven peptides contained four horses out of the
relevant five that displayed this pattern of abundance for fibronectin. Three of the eleven
peptides showed all five relevant horses exhibiting this abundance pattern. When percent
differences from day 0 abundance were determined, fibronectin displayed an opposite
pattern to the previous three biomarkers. This protein exhibited upregulation at all 12 time
points, from day 1 to day 62. The days that showed a distinct upregulation were days 7, 18,
21, 28, 31, 34, 57, and 62 with their percent differences above 100. Day 18 exhibited an
upregulation higher than that of day 7 at 147% compared to 105. Day 28 displayed a 138%
percent difference and day 34 exhibited a 133% percent difference. This can be seen in
Figure 3-1D. Fibronectin displayed downregulation on day 7 and upregulation on day 18
and these patterns are portrayed in Figure 3-2D. As shown in Figure 3-1D, no time points
were downregulated in comparison with day 0. This is true for Figure 3-2D, as well. This
graph shows day 0 abundance at below 1e9, while all subsequent time points are above
1e9. SE was calculated for each time point and was presented in this figure but is not
prominent due to its small variance. Fibronectin’s patterns of abundance that are opposite
to the other three key protein biomarkers are also displayed in the peak area graph in Figure
3-3D.

3.4

Discussion
Patterns exhibited by the four biomarkers that were identified in the discovery phase

were replicated in the targeted phase with greater intensity. The main pattern of actin,
carbonic anhydrase, and fibrinogen was upregulation at day 7 and downregulation at day
18; while the main pattern of fibronectin was downregulation at day 7 and upregulation at
day 18. The first three biomarkers also exhibited upregulation at the next relevant time
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point after day 18, and fibronectin displayed downregulation at the next time point after
day 18. While these abundance changes were distinct in the discovery phase of this project,
they were much clearer when targeted methodologies were employed.
Protein patterns were seen with greater intensity in this phase because PRM moves
away from the global scan performed with discovery. This technique searches for specific
peptides that were identified previously and results in clearer patterns. In the targeted
phase, equine sera samples were prepared in duplicate and injected in duplicate. There is
clear variability between replicates one and two and this may be due to a variety of factors.
While each replicate had duplicate samples which were prepared at the same time,
replicates one and two were prepared on different days and were ran separately on the
Orbitrap mass spectrometerd. This may have contributed to the variability seen in the
replicates. Peptide variability may be due to pipetting error, calibration variableness when
injecting the samples, or process variation during the tryptic digestion. However, the
patterns established from the discovery phase were still evident in the targeted phase:
upregulation at day 7 and downregulation at day 18 for actin, carbonic anhydrase, and
fibrinogen; and downregulation on day 7 and upregulation on day 18 for fibronectin.
Replicate variability is important to consider while analyzing this data, and indicates the
need for more sample runs to further confirm the patterns that were observed.
Figure 3-2A-D represents the relative abundances of the top three peptides of each
protein along with each time point’s SE. This graph mirrors Figure 2-1A-D; however, clear
differences can be seen. The SE bars in the discovery figure are extremely evident and are
meant to show how accurately the samples represent the population. The standard error
bars in the targeted figure are not visible at all. This is because the targeted methodology
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chooses the most optimal peptides out of all those displayed in discovery. The targeted
figure also displays abundances that are, at maximum, a 2-log increase compared to
discovery abundances. This is due to PRM creating more distinct patterns since it is no
longer performing a global scan. Abundances are greater for the targeted phase where the
top three peptides were summed together than it is for the discovery phase where the
abundances were calculated by determining the mean of abundances for all horses
represented at each time point.
The abundance at each time point was measured as compared to the abundance at day
0 for each of the four biomarkers. This can be found in Figure 3-1 A-D. Actin, carbonic
anhydrase, and fibrinogen all showed upregulation and downregulation in abundance
compared to day 0. The patterns established from the discovery methodology for these
three proteins, seen in Figure 2-2 A-D, are much more obvious through the PRM method.
Fibronectin exhibited a downregulation in abundance on day 7 and an upregulation on day
18. The figure for fibronectin’s percent difference in abundance compared to day 0 has no
bars that fall below the central line, indicating no downregulation in this protein. However,
on day 7, fibronectin is 105% upregulated from day 0, and day 18 is 147% upregulated
from day 0. While there may be no visible downregulation in comparison with day 0, these
percent differences indicate that day 18 is still upregulated compared to day 7. Furthermore,
according to the patterns established in the discovery phase, the next relevant time point
should be downregulated compared to day 18. Day 21 shows a 103% upregulation
compared to day 0, which is less than the upregulation seen on day 18, indicating
downregulation.
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All four biomarkers that were identified in the discovery phase and validated in the
targeted phase have relevance to bone remodeling and some possible association to
bisphosphonate administration. When bone remodeling begins, osteoclasts are activated to
resorb bone. They do this by adhering to the bone surface through the formation of
podosomes and, eventually, a sealing zone (Han et al., 2019). To resorb the bone, they must
acidify the matrix. This is accomplished with the protons that are produced from the
reaction that converts carbon dioxide into bicarbonate (Riihonen et al., 2007). Once bone
resorption is finished, the bone remodeling unit initiates bone ossification with the help of
osteoblasts. Bisphosphonates, once administered, can inhibit the bone resorption process,
and may increase bone ossification by improving the viability of osteoblasts.
Actin is a protein found in the podosomes of osteoclasts and is likely upregulated
when osteoclasts are activated (Destaing et al., 2003). Since bisphosphonates cause
apoptosis of osteoclasts in order to disrupt resorption, actin would expectedly be
downregulated when these drugs are administered. This upregulation followed by
downregulation was exhibited in the discovery phase and is seen with greater intensity in
this phase on days 7 and 18, respectively.
Carbonic anhydrase is the enzyme responsible for the catalysis of carbon dioxide to
bicarbonate, where the byproduct is protons (Riihonen et al., 2007). These protons, as
previously stated, are needed for the acidification of the bone matrix and, subsequently, the
resorption process. So, this biomarker is likely upregulated with the activation of
osteoclasts and downregulated with the apoptosis of osteoclasts that is caused by
administration of bisphosphonates. Actin and carbonic anhydrase both display these
changes in abundance on days 7 and 18 and this pattern is repeated in the targeted phase.
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Fibrinogen is a protein that is found on the surface of osteoclasts and may be an
exogenous activator of the bone-resorbing cell (Athanasou et al., 1988; Cole et al., 2014).
This biomarker would be expected to increase in abundance when osteoclasts are activated
and decrease when osteoclasts go through apoptosis due to bisphosphonate action.
Fibrinogen is upregulated on day 7 and downregulated on day 18 in both phases of this
study.
Fibronectin, the final biomarker identified and validated, is the earliest protein
synthesized by osteoblasts for ossification and production of the bone matrix (Tang et al.,
2004). Osteoblasts are responsible for the part of bone remodeling that is not inhibited by
bisphosphonates and may be increased due to improved activity of these cells. This protein
showed a trend opposite to the previous three proteins: downregulation on day 7 and
upregulation on day 18. This pattern is shown clearly in the targeted phase of this study,
repeated from the discovery phase. The downregulation is likely due to inactivity of
osteoblasts while osteoclasts are resorbing bone. The upregulation occurred when
bisphosphonates caused apoptosis of the osteoclast and may have increased the viability of
the osteoblast to ossify bone.
Overall, the trends established in the discovery phase were repeated in the targeted
phase with greater intensities. PRM allowed for a more specific scan of the initially
identified peptides and the establishment of repeatability for the abundance patterns seen
in discovery. These biomarkers, because of their involvement in bone remodeling units,
may be good candidates for the detection of prohibited bisphosphonate use when drug
testing racehorses.
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3.5

Other Possible Causes of Protein Changes
These four proteins, as discussed in Chapter 2, can be found in other areas of the

body. Actin, for example, is important in the cell mobility and migration of all cells. The
changes observed in actin could be due to other cells preparing for migration within the
biological system. Because actin is located inside the osteoclast, apoptosis and lysis of the
cell may have caused transitory changes in the abundance of actin that was observed.
Carbonic anhydrase, as discussed in Chapter 2, is found in erythrocytes and large
intestine cells. Changes observed in this protein may be due to physical activity, stressors,
or other factors that affect red blood cells or large intestine parameters.
Fibrinogen is a protein that is affected by inflammation, as well as changes to red
blood cells. Changes observed in this protein may also be due to physical activity, stressors,
or other factors affecting inflammation or erythrocytes.
The final biomarker, fibronectin, is a protein which is found in the extracellular
matrix of all cells, including bone. The changes in this protein may have been due to normal
cellular turnover that occurs throughout the biological system, as it does in bone cells.
Although these proteins are not isolated to bone cells or the bone matrix, their similar
abundance patterns following bisphosphonate administration and their association with the
bone matrix in some form indicate that their changes may still be associated with
bisphosphonate use. Their role in other cells of the biological system indicate a need to
increase the specificity at which they are associated with the bone matrix. This may be
accomplished in future work.
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3.6

Limitations of the Study
A limitation of this study is the lack of a negative control. A negative control would

have been a horse or horses that were not administered any substance, including
bisphosphonates, and were assumed to be normal. Blood samples would have been taken
at the same time points as the 19 equine subjects in this study to act as a comparator. This
would allow for more confirmatory identification and validation of the four biomarkers
that are postulated to change at certain time points as a result of bisphosphonates being
administered. Because these horses had an underlying need for bisphosphonate treatment,
it would be beneficial to have a group of horses which did not need this anti-resorptive
drug in order to observe how the protein changes are affected.
These horses were not sampled at common time points throughout the study. Having
a group of horses that are administered bisphosphonates and have blood samples collected
on the same days would aid in confirming any trends that were observed. Another
limitation is the lack of several time points for each horse. The horse with the most samples
taken was sampled nine times. If there were more time points collected, clearer trends may
be seen in the horse.
Because the horses were anonymous, this limits the ability to attribute trends in
proteins to factors like age or sex. Though these protein changes may not be due to these
factors, having that information would allow for more confirmation that these biomarkers
are optimal candidates for bisphosphonate administration. None of these proteins are
specific to the bone remodeling process and are often found elsewhere in biological
systems. However, the repeatability of their patterns from the discovery phase to the
targeted phase and their association with bone turnover, is important and may indicate their
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response to bisphosphonates affecting the bone remodeling process. There is also a need
to identify more biomarkers that can confirm the administration of bisphosphonates and
are more specific to bone remodeling processes.
The depletion methods in this study could also be improved so that background noise
in the mass spectrometerd is reduced, and more relevant proteins can be identified and
validated. These samples could also be analyzed on a different instrument, such as a triple
quadrupole mass spectrometer, to compare the data that is generated and further confirm
the results from the discovery and targeted phases of this study.

3.7

Future Work
This study represents an excellent starting point at which to identify biomarkers for

bisphosphonate administration. However, more work remains to be done in order to verify
that the biomarkers which were changed were changed in response to bisphosphonates and
are specific to bone turnover. There is also a need to complete the same project with the
other non-nitrogen containing bisphosphonate, clodronate. By administering clodronate to
a group of horses and assessing the protein effects in the same way, it would allow for more
confirmation that these proteins changed in response to a non-nitrogen containing
bisphosphonate.
Because there are two different classes of bisphosphonates, it would be worthwhile
to assess off-label use of nitrogen-containing bisphosphonates on the horse. This class has
a different mechanism of action to induce osteoclast apoptosis and may result in different
protein changes than that of the non-nitrogen containing bisphosphonates.
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Since these biomarkers will eventually be integrated into the Equine Biological
Passport, following more confirmatory studies, it is important that this same procedure be
applied to other drugs, as well. These drugs may include growth promoters or respiratory
drugs that alter the performance of the racehorse and affect certain proteins within the
biological system.
Future work remains in order to further confirm these four protein biomarkers,
identify more proteins that are changed in response to bisphosphonates, and assess the
protein effects of other classes of drugs with the overarching goal of protecting the welfare
of the horse and the integrity of the breeding industry.

3.8

Conclusion
Patterns identified in the discovery phase for the four biomarkers were repeated in

the targeted phase in all replicates with greater intensities. While not every horse was
sampled on days that showed the most distinct patterns (e.g., day 7 and day 18), those with
the relevant time points exhibited clear trends of upregulation and downregulation on these
days.
Actin showed upregulation on day 7, downregulation on day 18, and upregulation at
the next time point, whether that was day 21, 28, 42, or 49. This trend was exhibited in the
actin’s top four peptides for both replicates. Its significance is its presence in podosomes
of osteoclasts, which are directly affected by bisphosphonates. While actin is not a protein
that is specific to bone remodeling, the repeatability of its pattern is indicative of a
relationship to the administration of bisphosphonates.
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Carbonic anhydrase was upregulated on day 7, downregulated on day 18, and
upregulated on days 21, 28, 42, and 49, depending on what day the horse was sampled.
This was true in both replicates. Carbonic anhydrase, because of its catalytic activity in the
production of protons to aid the osteoclast in resorbing the bone matrix, is likely a good
indicator of bisphosphonate administration. This protein also exhibited repeatability that
further confirms its association in these processes.
The third biomarker that was identified and validated, fibrinogen, exhibited the same
pattern of upregulation on day 7 and downregulation on day 18 in both replicates. While
its association with the bone remodeling process is not as definitive as actin or carbonic
anhydrase, its presence on the surface of osteoclasts and because it is postulated to be an
exogenous activator of bone resorption, the upregulation and downregulation seen on these
days is indicative of a connection to bisphosphonate administration.
The fourth and final biomarker that exhibited an opposite trend from the first three
proteins is fibronectin. Its downregulation on day 7 and upregulation on day 18 seen in
both replicates suggests an association with bone remodeling and, therefore,
bisphosphonate administration. Because of its relationship to osteoblasts, a cell type that
executes the opposite action of osteoclasts, and its opposite trend compared to the three
biomarkers associated with osteoclasts, fibronectin is likely a good biomarker of
bisphosphonate use.
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TABLES
Table 3-1: Four Key Proteins and Their 23 Unique Peptides1

AGFAGDDAPR
DLYANTVLSGGTTMYPGIADR
GYSFTTTAER
HQGVMVGMGQK

488.7277
1108.0386
566.7671
391.1952

Retention
Time
16.1
34.7
18
15.7

AVQQPDGLAVVGVFLK

820.9721

37.3

SLLSNVEGGK
YSAELHLVHWNSSK

502.2745
557.6143

20.6
20.4

(C) Fibrinogen

DNCCILDER
FLQDIYNSNNQK
HPGSSEPGSDGLQK
IAIGEGQQFHLGAAK
TFPGEGSLDGLFHR

597.7475
742.3624
465.8881
513.9474
511.5879

19.3
21.7
14.9
21.5
30.5

(D) Fibronectin

ATITGYR
GATYNIIVEALK
IFAVNHGR
ISCTIANR
ITIMWTPPESAVTGYR
ITYGETGGNSPVQEFTVPGSK
LDAPTNLR
NTFAEVTGLSPGVTYHFK
SYTITGLQPGTDYK
TYHVGEQWQK
VDVLPVNLPGEHGQR

391.2137
646.3664
457.2537
467.7423
911.4638
723.3550
450.2508
656.6669
772.3855
425.8754
543.9617

15.9
32.3
15.4
15.7
33.3
27
17.1
28.8
23.7
16.3
23.9

Protein
(A) Actin

(B) Carbonic
Anhydrase

Peptide

1

m/z

The 23 unique peptides that were chosen based on peak area, fragment ion ppm tolerance, retention
time, and number of detectable transitions. Included in this table are the peptides’ m/z as well as
their retention times found in Skylineg software.
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Figure 3-1 A-D: Percent Difference of Identified Biomarker Abundance with Day 0 Abundance.
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Figure 3-1: (A) The abundance patterns of actin when compared with the abundance at day 0.
(B) Carbonic anhydrase abundance patterns in comparison with the abundance at day 0. (C) The
abundance patterns of fibrinogen compared to the abundance of fibrinogen at day 0. (D)
Fibronectin abundance patterns compared to day 0 abundance.
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Figure 3-2 A-D: Global PRM Figure of Top Three Peptides Per Protein Summed for
Abundance and Standard Error of Population.

84

Figure 3-2: For each protein, the top three peptides were summed to calculate abundance and
standard error. (A) The abundance of actin at each time point, representing all 19 horses, along
with the standard error of population. (B) The abundance of carbonic anhydrase from day 0 to
day 62 along with the standard error of population. (C) Fibrinogen abundance patterns and
standard error. (D) The abundance and standard error of fibronectin at each time point, from day
0 to day 62.
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Figure 3-3 A-D: Peak Areas of Four Key Proteins Across Eight Time Points.
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Figure 3-3: (A) The peak area replicate comparison graph for actin created in Skylineg
software. (B) The Skylineg software graph for carbonic anhydrase peak areas. (C) The peak
areas of fibrinogen for the same horse represented in the previous two graphs, also created in
Skylineg. (D) The peak areas of fibronectin created in Skylineg.
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Figure 3-4 A-D: MS2 Fragmentation Spectra for Four Key Protein Biomarkers.
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Figure 3-4: The peptides used in this figure are the same peptides used for Figure 3-3 A-D. (A)
The MS2 fragment spectrum for the protein actin. (B) This is a depiction of the MS2 fragment
spectrum for carbonic anhydrase. (C) This is the MS2 fragment spectrum for the third key protein
biomarker, fibrinogen. (D) The MS2 fragment spectrum of the protein fibronectin.
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APPENDICES
APPENDIX I: GLOSSARY
Abbreviation

Explanation

AGC

Automatic Gain Control

DDA

Data-Dependent Acquisition

ESI

Electrospray Ionization

FDR

False Discovery Rates

FWHM
HCD
LC-MS/MS

Full Width at Half Maximum
Higher Energy C-trap Dissociation
Liquid Chromatography with Tandem Mass Spectrometry

LFQ

Label-Free Quantitation

LOD

Limit of Detection

MALDI
MRM
m/z

Matrix-Assisted Laser Desorption Ionization
Multiple Reaction Monitoring
Mass-to-Charge Ratio

PRM

Parallel Reaction Monitoring

PSM

Peptide Spectra Match

Q1

First quadrupole mass filter
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Q2

Quadrupole collision cell

Q3

Second quadrupole mass filter

SRM

Single Reaction Monitoring

tMS2

Targeted MS2
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APPENDIX II: VENDORS
a. AcclaimTM PepMapTM Trap Column: Thermo Fisher Scientific™
b. Double-distilled water: MilliPore Milli-Q Water
c. Easy Spray PepMapTM RSLC C18 Column: Thermo Fisher Scientific™
d. Orbitrap™ Exploris 480 Mass Spectrometer: Thermo Fisher Scientific™
e. Proteome Discoverer™ Version 2.4: Thermo Fisher Scientific™
f. Savant SpeedVac SPD1030 Integrated Vacuum Concentrator: Thermo Fisher
Scientific™
g. Skyline Version 21.2.0.425: MacCoss Lab, Department of Genome Sciences,
University of Washington
h. Sorvall Legend Micro 21 Centrifuge: Thermo Fisher Scientific™
i. Sorvall X Pro Series Refrigerated Centrifuge: Thermo Fisher Scientific™
j. Ultimate 3000 RSLCnano: Thermo Fisher Scientific™
k. Vacuum Manifold: Alltech
l. Vortex-Genie 2: Scientific Industries
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